



Cite this: *RSC Adv.*, 2021, **11**, 25228

Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer

Nitin Tandon,^a Vijay Luxami,^b Divya Kant,^a Runjhun Tandon^{*a} and Kamaldeep Paul^{ID *b}

The indazole core is an interesting pharmacophore due to its applications in medicinal chemistry. In the past few years, this moiety has been used for the synthesis of kinase inhibitors. Many researchers have demonstrated the use of indazole derivatives as specific kinase inhibitors, including tyrosine kinase and serine/threonine kinases. A number of anticancer drugs with an indazole core are commercially available, e.g. axitinib, linifanib, niraparib, and pazopanib. Indazole derivatives are applied for the targeted treatment of lung, breast, colon, and prostate cancers. In this review, we compile the current development of indazole derivatives as kinase inhibitors and their application as anticancer agents in the past five years.

Received 22nd May 2021
 Accepted 29th June 2021

DOI: 10.1039/d1ra03979b
rsc.li/rsc-advances

1. Introduction

Cancer is a disease that causes uncontrollable abnormal cell growth, which can start in any organ of the body and further spread to distant organs. Cancer is the second leading cause of deaths globally, which has led to almost 9.6 million deaths in 2018 and accounted for 1 out of 6 deaths according to the World Health Organization (WHO).¹ The treatment of cancer includes

^aSchool of Chemical Engineering and Physical Sciences, Lovely Professional University, Phagwara-144411, India. E-mail: gupta.runjhun@gmail.com

^bSchool of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala-147004, India. E-mail: kpaul@thapar.edu



Dr Nitin Tandon received his M.Sc. Degree from Guru Nanak Dev University and PhD in Organic Chemistry from Rajasthan University, India. He is working as an Associate Professor in the School of Chemical Engineering and Physical Sciences, Lovely Professional University, Punjab, India. His area of research is the multistep synthesis of organic compounds including heterocyclic moieties of medicinal interests and preparation of nano-catalysts for their applications in green chemistry.

surgery, radiation therapy, chemotherapy, immunotherapy, hormonal therapy, targeted therapy and synthetic lethality. The location of cancer cells, the stage of cancer, the age of the patient and the general state of the patient are some of the factors that decide the therapy to be used. The probability of cancer cells affecting the adjacent tissues or organs limits the use of surgery, whereas the use of chemotherapy and radiation therapy is associated with negative effects on normal cells.²⁻⁵ One of the possible pathways leading to this deadly disease is the mutation of various types of genes including kinases, which can trigger diverse cellular anomalies, leading to the initiation of cancer. The human genome includes 518 protein kinases,



Dr Vijay Luxami received her PhD from the Department of Chemistry, Guru Nanak Dev University Amritsar. She joined the School of Chemistry and Biochemistry, Thapar Institute of Engineering and Technology, Patiala as an Assistant Professor in 2010. She has received various awards including the DST Young Scientist, DST INSPIRE Faculty, and DST-DFG awards. She worked as a Visiting Scientist at the University of Bath, UK. Currently, she is working as an Associate Professor at TIET, Patiala. Her area of research is organic supramolecular materials and their applications in molecular electronics.



where the most probable mutations occur in BRAF,^{6,7} KIT,⁸ EGFR⁹ and FTL3,¹⁰ whereas some kinases are regulated by epigenetic mechanisms such as RET,^{11,12} AATK,¹³ EPHA5,¹⁴ CHK2 (ref. 15) and PKD1.¹⁶ Phosphorylation is one of the important steps involved in the cell cycle, growth, apoptosis, motility, proliferation, *etc.* Inhibition of kinase activity has a profound effect on this process. In addition, mutation or de-regularization of kinase activity has been proven to be oncogenic and has potential to inhibit the spread of cancer cells.¹⁷ Considering that kinases play an important role in cell biology, many attempts have been made to develop novel kinase inhibitors such as tyrosine kinase,¹⁸ cyclin-dependent kinase,^{19–21} aurora kinase,^{22,23} EGFR²⁴ and VEGFR,²⁵ which can serve as potential drugs candidates.

Many derivatives of primidine,²⁶ benzimidazole,²⁷ benzothiazole,²⁸ coumarin,²⁹ naphthalimide,^{30,31} *etc.* have been used as potential kinase inhibitors as possible treatment for cancer. Indazole derivatives possess a wide range of pharmacological activities such as antibacterial, antifungal, anti-inflammatory, anti-HIV, anti-arrhythmic and anti-tumor.^{32–37} The aim of this review is to compile the work performed by different research groups in the field of indazole derivatives as kinase inhibitors. These indazole derivatives have been synthesized using various synthetic methodologies (Fig. 1). Further, the data has been compiled from 2015–2021, which will be beneficial to researchers for the design and synthesis of novel indazole derivatives with desired therapeutic outcomes.

2. Mono-kinase inhibitors

(i) Vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitors

Vascular endothelial growth factor receptor is a signaling protein involved in angiogenesis and vasculogenesis. There are three types of VEGFR, namely VEGFR-1, VEGFR-2 and VEGFR-3. VEGFR-2 is known to mediate all cellular responses of VEGFR.³⁸



Dr Runjhun Tandon is working as an Associate Professor in Lovely Professional University. She obtained her BSc and M.Sc. from Lucknow University and PhD degree from Rajasthan University, India. Her research work includes the synthesis of heterocyclic compounds of medicinal use and their polymorphic studies and synthesis of novel nanocatalysts and their applications in various synthetic reactions for the preparation of organic molecules of industrial and medicinal importance by using green chemistry principles.

They are also known as kinase insert domain receptor (KDR) inhibitors, which can affect multiple signaling pathways such as tumor angiogenesis, proliferation and metastasis. VEGFR has been found to be overexpressed in many cancer types such as melanoma, medulloblastoma and ovarian cancer.³⁹ A reduction in VEGFR-2 results in a reduction in blood flow to tumor cells, thereby suppressing tumor angiogenesis.⁴⁰

Czaja *et al.* studied arylsulphonyl indazole derivatives (Fig. 2) and their interactions with VEGFR2 kinase using docking, MD simulation and other computational methods.⁴¹ These studies suggested that compounds **1–6** and **9** are superimposable in their docked conformers with protein (PDB code: 3EWH)⁴² having an interaction energy in the range of -36.5 to -66.5 kcal mol $^{-1}$. However, the dissimilar orientation of the indazole ring in compound **7** led to different sets of interactions with VEGFR2 kinase compared to the other derivatives. Compounds **1–6** and **9** were stabilized by hydrogen bonding and π – π stacking. Further exploration of these compounds for their cytotoxic activity against the human colon adenocarcinoma cancer cell line (HT-29), Michigan Cancer Foundation-7 cancer cell line (MCF-7) and MD Anderson-Metastatic Breast-231 cancer cell line (MDA-MB-231) suggested that compounds having pyrazole (**3**), indole (**6**) and carbazole (**7**) moieties possessed good cytotoxic activity, whereas compounds having chloro (**1**) and pyrazole (**8**) moieties were observed to be the weakest cytotoxic agents.

Elsayed *et al.* reported the activity of a series of quinazoline derivatives of indazole (Fig. 3) against VEGFR-2.⁴³ Derivatives **11a–f** exhibited better activity than **10a–d** because of the presence of methoxy group(s) on the benzamide ring, with **11a** being the most potent derivative, whereas thio derivative **11f** exhibited the lowest activity. Interestingly, **12a–e** possessed excellent activity against VEGFR-2, with **12b**, **12c** and **12e** exhibiting better activity (IC_{50} values of 5.4, 5.6 and 7 nM, respectively) than sorafenib (IC_{50} = 90 nM). An increase in bulkiness at the terminal phenyl ring resulted in better activity in the case of



*Dr Kamaldeep Paul received his Master's Degree from the Department of Pharmaceutical Sciences in 2000, and PhD in Synthetic Organic and Medicinal Chemistry from the Department of Chemistry, Guru Nanak Dev University, Amritsar in 2006. Presently, he is working as a Professor in the School of Chemistry and Biochemistry, Thapar Institute of Engineering & Technology, Patiala, India. He has 85 research publications in peer-reviewed journals. His area of research is synthetic organic and medicinal chemistry, where his research is broadly focused on the multistep synthesis of heterocyclic molecules, C–H functionalization and their *in vitro* evaluation for anticancer and antimicrobial activities.*






Fig. 1 Pathways for the synthesis of indazole derivatives.




Fig. 2 Arylsulphonyl indazoles as VEGFR2 kinase inhibitors.


12b, 12c and 12e. Further, compound **11a** exhibited significant inhibitory activity against a non-small cell lung cancer cell line (NCI-H322M) ($GI = 60\%$) and human breast adenocarcinoma cancer cell line (MDAMB-468) ($GI = 90\%$), whereas **12b** was found to be selective against a colorectal cancer cell line (KM12) ($GI = 74\%$). Derivatives **12a** and **12c** showed profound anti-cancer activity against a full panel cell line with **12a** showing sub-micromolar activity.

Later, Elsayed *et al.* reported indazole-pyrimidine-based derivatives substituted at the 2-position of the pyrimidine ring as VEGFR-2 inhibitors, where compound **13a-j** exhibited better inhibitory properties (Fig. 4).⁴⁴ The presence of hydrophobic groups such as alkyl or halogen (**13a-d**) led to a decrease in potency compared to a methoxy derivative (**13e** and **f**). Conversely, hydrogen bond-forming groups such as amide (**13f** and **13g** with $IC_{50} = 114$ and 57.9 nM, respectively) and sulfonamide (**13i**, $IC_{50} = 34.5$ nM) resulted in enhanced activity compared to pazopanib ($IC_{50} = 30$ nM).

(ii) Fibroblast growth factor receptor (FGFR) inhibitors

Fibroblast growth factor receptor (FGFR) inhibitors are a class of tyrosine kinase receptors, which play an important role in cell






11a. $R_1 = -OCH_3$, $X = O$, $R_2 = 3-Cl$, $4-CH_3$
11b. $R_1 = -OCH_3$, $X = O$, $R_2 = -3,4-Cl$
11c. $R_1 = -OCH_3$, $X = O$, $R_2 = 3-Br$
11d. $R = -OCH_3$, $X = O$, $R_2 = -2,4-OCH_3$, $5-Cl$
11e. $R = -OCH_3$, $X = O$, $R_2 = H$
11f. $R = -OCH_3$, $X = S$, $R_2 = H$

12a. $R_3 = H$; **12b.** $R_3 = 3-Cl$, $4-CH_3$
12c. $R_3 = 3,4-Cl$; **12d.** $R_3 = 3-Br$
12e. $R_3 = 2,4-OCH_3$, $5-Cl$

Fig. 3 Indazole derivatives with different substitution patterns as VEGFR-2 kinase inhibitors.



13a. $R = 4-CH_3$, **13b.** $R = 4-F$
13c. $R = 4-Cl$, **13d.** $R = 3,4-Cl$
13e. $R = 3-OCH_3$, **13f.** $R = 4-OCH_3$
13g. $R = 4-NHCOC_3$, **13h.** $R = 3-NHCOC_3$, $4-Me$
13i. $R = 4-SO_2NH_2$, **13j.** $R = 2-CH_3$, $5-NO_2$

Fig. 4 Indazole-pyrimidine-based derivatives as VEGFR-2 inhibitors.

development and growth.^{45,46} They can be categorized as FGFR1 to FGFR4 with a variation in their sequence identity from 56–71%.⁴⁷ FGFRs play a crucial role in important physiological processes such as cell migration, survival, proliferation and differentiation.^{48–50} Dysregulation of FGFR is associated with many types of cancers such as ovarian cancer, urothelial carcinoma, lung adenocarcinoma and hepatocellular carcinoma.^{51,52} Erdafitinib, a pan-FGFR inhibitor, has been approved by the USFDA for the treatment of urothelial carcinoma.

Liu *et al.* reported derivatives with varying substitution at the phenyl ring of indazole as FGFR1 inhibitors (Fig. 5).⁵³ The structure–activity relationship (SAR) studies of the synthesized derivatives (**14a–e**) revealed that the substitution of the 3-methoxyphenyl group on the phenyl ring (**14a**, $IC_{50} = 15$ nM) with larger groups such as 3-ethoxyphenyl (**14b**, $IC_{50} = 13.2$ nM) and 3-isopropoxyphenyl (**14c**, $IC_{50} = 9.8$ nM) led to an increase in activity. Interestingly, the presence of an additional fluorine atom on the phenyl ring led to a remarkable improvement in




Fig. 5 Indazole derivatives as inhibitors of FGFR1.







Fig. 6 Superimposed docking structures of **14b** (white) and **14c** (yellow) with FGFR1 (4ZSA) (no permission required).

activity (**14d**, $IC_{50} = 5.5$ nM) compared to its counterpart **14a** ($IC_{50} = 15$ nM). Moreover, **14e** was found to be selective against FGFR1 compared to the other FGFR, anaplastic lymphoma

kinase (ALK), ephrin type-A receptor 2 (EPH-A2) and breakpoint cluster region protein (Bcr-Abl). Further, docking studies of these compounds in the ATP binding pocket of FGFR1 predicted various interactions such as hydrogen bonding and hydrophobic interactions through the indazole N-H and 3-methoxyphenyl group.

Docking studies of **14b** and **14c** with the ATP-binding pocket of FGFR1 (4ZSA) revealed that the N-H of the indazole ring formed a hydrogen bond with Glu562, whereas the nitrogen atom of the indazole group and N-H of the amide bond formed a hydrogen bond with Ala564. The corresponding ethoxy and iso-propoxy groups of compounds **14b** and **14c** filled the hydrophobic cavity tightly, resulting in the high potency of these derivatives (Fig. 6).

Turner *et al.* reported the structure-based design and synthesis of indazole derivatives (Fig. 7) for their exploration as inhibitors of FGFR1 kinases.⁵⁴ The initial screening supported the importance of the indazole group with nitrogen at the 2-position, given that compounds **15–17** did not show the



15. $R_1 = Y = X = R_2 = H$; **16.** $R_1 = X = R_2 = H, Y = N$
17. $R_1 = Cl, Y = N, X = R_2 = H$; **18.** $R_1 = Y = R_2 = H, X = N$
19. $R_1 = R_2 = H, Y = X = N$; **20.** $R_1 = F, R_2 = Y = H, X = N$
21. $R_1 = Cl, R_2 = Y = H, X = N$; **22.** $R_1 = OEt, R_2 = Y = H, X = N$
23. $R_1 = Y = H, R_2 = OH, X = N$; **24.** $R_1 = R_2 = Y = H, R_2 = OMe, X = N$
25. $R_1 = Y = H, R_2 = Cl, X = N$

Fig. 7 Structure-based design of indazole derivatives as inhibitors of FGFR1 kinases.




Fig. 8 1H-Indazol-3-amine derivatives as inhibitors of fibroblast growth factor receptor.






Fig. 9 Predicted docking of **27a** with FGFR1 (reproduced with permission; License Number: 5087581066045).

required inhibition against FGFR-1. Further, the presence of a pyridine ring led to a decrease in IC_{50} value for compound **19** ($IC_{50} = 90 \mu\text{M}$) compared to compound **18** ($IC_{50} = 77 \mu\text{M}$) bearing a phenyl substituent. Compound **22** was also found to inhibit FGFR-2 and FGFR-3 with IC_{50} values of 0.8 and $4.5 \mu\text{M}$, respectively, and possessed 2.5-fold activity against FGFR-2 over FGFR-1. Compound **23** exhibited an IC_{50} value of $2 \mu\text{M}$ compared to **24** and **25**, emphasizing the importance of the H-donor OH group.

Cui *et al.* reported *1H*-indazol-3-amine derivatives (Fig. 8) as inhibitors of fibroblast growth factor receptors FGFR1 and FGFR2.⁵⁵ Their studies suggested that the presence of fluorine substitution in ring B or ring C was not tolerated (**26a–e**). However, the presence of fluorine substitution at 6-position of ring A resulted in improved enzymatic activity and cellular potency (**27a**, FGFR1 $IC_{50} < 4.1 \text{ nM}$, FGFR2 $IC_{50} = 2.0 \text{ nM}$, Koeffler Golde-1 (KG1) $IC_{50} = 25.3 \text{ nM}$, and (SNU) $IC_{50} = 77.4 \text{ nM}$). Further, compounds **27a**, **27c** and **27f** were found to exhibit better activity than **27b**, **27d** and **27e**. In addition,

compound **27a** showed high affinity towards the FGFR1 enzyme (PDB code: 4ZSA⁵⁶) in the docking studies.

The binding mode of **27a** with FGFR1 (Fig. 9) revealed that this derivative was tightly bound to the ATP binding site of FGFR1. The 3-aminoindazole group occupied the hinge region and formed three hydrogen bonds with Ala564 and Glu562, whereas the phenyl ring of the indazole moiety participated in π - π stacking with Phe489. Interestingly, the methoxy oxygen of **27a** participated in hydrogen bond formation with Asp641, whereas the fluorine atoms formed hydrophobic interactions with Val492 and Ala640.

Zhang *et al.* reported 6-(2,6-dichloro-3,5-dimethoxyphenyl)-4-substituted-1*H*-indazole derivatives (Fig. 10) as FGFR inhibitors.⁵⁷ The introduction of an acetyl or methoxy group at the *meta* position of the phenyl ring of **28a** (enzyme inhibition at $58.8 \mu\text{M}$ with $IC_{50} = 69.1 \text{ nM}$) led to an increase in activity against FGFR1 (enzyme inhibition: $76.4 \mu\text{M L}^{-1}$ and $57.0 \mu\text{M L}^{-1}$ for **28b** and **28d**, respectively) compared to the *para* position (enzyme inhibition: $32.2 \mu\text{M L}^{-1}$ and $11.9 \mu\text{M L}^{-1}$ for **28c** and **28e**, respectively). Substitution by a methylcarbamoyl group enhanced the activity (**30b**, $IC_{50} = 38.6 \text{ nM}$) and the 4-methylpiperazine analogue (**31**) exhibited remarkable activity ($IC_{50} = 30.2 \text{ nM}$).

Liu *et al.* reported novel methylketo derivatives containing a piperazine moiety (Fig. 11) as inhibitors of FGFR.⁵⁸ Modification at the piperidine ring of **32** led to a decrease in the activity of **33a** against FGFR1 from an IC_{50} value of $14.6 \text{ to } 25 \text{ nM}$. However, the replacement of the phenyl ring of **33b** ($IC_{50} = 40.4 \text{ nM}$) with pyridine (**33c** and **d**, $IC_{50} > 1000 \text{ nM}$), thiophene (**33e**, $IC_{50} > 1000 \text{ nM}$) and introduction of a fluorophenyl (**33f**), trifluoromethyl phenyl (**33g**) or methoxyphenyl (**33h–j**) group at the *para* position led to a decrease in activity with IC_{50} values near 1000 nM . Interestingly substitution with a methoxy group at the *meta* position of the phenyl ring led to improved activity (**33k**, FGFR1 $IC_{50} = 15 \text{ nM}$; Seoul National University cancer cell line (SNU-16) $IC_{50} = 642.1 \text{ nM}$). Further optimization of **33b**




Fig. 10 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1*H*-indazoles as FGFR inhibitors.






Fig. 11 Novel indazole derivatives as inhibitors of FGFR.

with a halogen moiety at the *ortho* or *meta* position of the phenyl ring led to enhanced activity (33m-o, FGFR1 IC₅₀ = 2.9, 5.5 and 9.6 nM, respectively).

(iii) Epidermal growth factor receptor (EGFR) inhibitors

Epidermal growth factor receptor (EGFR) kinases also belong to the family of tyrosine kinases. Overexpression of EGFR is associated with gene mutation and amplification, resulting in

cell survival, invasion, metastasis, proliferation and prognosis. These kinases have been approved for the treatment of pancreatic, lung, and colorectal cancer and squamous cell carcinoma of the neck and head.⁵⁹

Tomassi *et al.* reported indazole-based covalent inhibitors (Fig. 12) of epidermal growth factor receptor (EGFR).⁶⁰ Initial screening suggested that the derivatives with an acrylamide moiety (34a and 35a) had enhanced activity compared to their




Fig. 12 Indazole-based covalent inhibitors of epidermal growth factor receptor (EGFR).






Fig. 13 Proposed docking models of 36a (A), 36d (B), 36g (C) and 37a (D) with EGFR (reproduced with permission).

reversible counterpart (34b and 35b), respectively. Further, 35a was found to be selective for the EGFR wild type with $IC_{50} = 3352$ and 462 nM against the L858R and L858R/T790M mutants, respectively. The introduction of a 1-naphthyl substituent (36b and 37a, $IC_{50} = 1\text{--}4.3$ nM and 1.1–8.1 nM, respectively) resulted in good activity with single-digit nM IC_{50} values compared to the 2-naphthylsubstituted derivatives (36a and 37b, $IC_{50} = 25\text{--}312$ nM and 2.7–33 nM, respectively) with better activity against human epidermoid carcinoma (A431), hepatocellular carcinoma (HCC827) and lung adenocarcinoma (H1975) cancer cell lines. Substitution with different heterocycles such as isoquinolin-4-yl and *N*-methylindol-3-yl resulted in better activity against EGFR, L858R and L858R/T790M mutants (36c and d, single-digit nM IC_{50} values) than the pyridine derivatives (36e and f, double-digit nM IC_{50}). Interestingly, the fluorinated derivative (36g) showed remarkable activity in the sub-nanomolar range against all variants of EGFR and EC_{50} values of 191 and 22 nM for H1975 and HCC827, respectively. Further, the docking models of 36a, 36d, 36g and 37a with EGFR supported the observed activity of these compounds (Fig. 13).

(iv) Interleukin-2-inducible T-cell kinase (ITK) inhibitors

Interleukin-2-inducible T-cell kinases (ITKs) are S member of the Tec family tyrosine kinases, which play a crucial role in the intracellular signaling of hematopoietic cells.⁶¹ Studies have established that a deficiency in ITK results in the suppression of cell proliferation,^{62–64} and abnormal values of ITK result in T-cell malignancies.^{65,66}

Heifetz *et al.* optimized indazole derivatives (Fig. 14) as interleukin-2-inducible T-cell kinase (ITK) inhibitors.⁶⁷

Compound 38a (PIE energy = -79.88 kcal mol $^{-1}$; ITK $K_i = 43$ nM) was taken as the lead compound for further optimization to discover 38b and 38c. The pair interaction energy (PIE) calculated using the fragment molecular orbital (FMO) method for 3k (-107.80 kcal mol $^{-1}$) was found to be better than 38b (-97.97 kcal mol $^{-1}$). The same trend was reflected by the calculated ITK K_i values, which were 7.8 nM for 38b and 0.8 nM for 3bc compared to 43 nM for 38a.

(v) pan-Tropomyosin receptor kinase (pan-Trk) inhibitors

Tropomyosin receptor kinases (TRKs) belong to the family of cell surface receptor tyrosine kinase (RTK) and are further classified into TRKA, TRKB and TRKC.⁶⁸ Various studies reported that TRKs can mediate cell proliferation, metabolism, differentiation and apoptosis.^{69–71} The abnormal expression of TRK can lead to various types of human cancers.^{72–75}

Shirahashi *et al.* reported 3-aryl-indazole derivatives as inhibitors (Fig. 15) of pan-Trk for the treatment of pain.⁷⁶ Among the synthesized compounds by varying the substitution in ring A, compound 39a with a methoxypyridine moiety was found to exhibit the highest potency but moderate metabolic stability. Replacement of the methoxy group with piperidine (39b) led to high cell permeability and significant potency (TRKA $IC_{50} = 1.6$ nM). Further optimization of 39b suggested that the non-branched nitrogen linker with phenyl ring B substituted at the 2-position by a sulfonamide group (39d) together with a fluoro group at the 5-position (39e) exhibited the highest cell permeability together with excellent potency among the synthesized compounds with TRKA IC_{50} values of 1.2 nM and 0.3 nm, respectively, compared to parent derivative 39c with






Fig. 14 Optimization of indazole derivatives as ITK inhibitors.





39a. $R_1 = \text{OMe}$, $R_2 = \text{H}$, $X = \text{C}$, $Y = \text{N}$, $L = \text{N}$, $R_3 = R_4 = R_5 = \text{H}$, $R_6 = 2\text{-NHSO}_2\text{Me}$
39b. $R_1 = \text{Piperidine}$, $R_2 = \text{H}$, $X = \text{C}$, $Y = \text{N}$, $R_3 = R_4 = R_5 = \text{H}$, $R_6 = 2\text{-NHSO}_2\text{Me}$
39c. $R_1 = \text{Piperidine}$, $R_2 = \text{H}$, $X = \text{C}$, $Y = \text{N}$, $L = \text{N}$, $R_3 = R_4 = R_5 = R_6 = \text{H}$
39d. $R_1 = \text{Piperidine}$, $R_2 = \text{H}$, $X = \text{C}$, $Y = \text{N}$, $L = \text{N}$, $R_3 = R_4 = R_5 = R_6 = 2\text{-SO}_2\text{Me}$
39e. $R_1 = \text{Piperidine}$, $R_2 = \text{H}$, $X = \text{C}$, $Y = \text{N}$, $L = \text{N}$, $R_3 = R_4 = R_5 = R_6 = 2\text{-SO}_2\text{Me-5-F}$

Fig. 15 3-Aryl-indazole derivatives as inhibitors of pan-Trk.

TRKA $\text{IC}_{50} = 73 \text{ nM}$. Docking studies against AZ-23 bound to the TRKA protein also supported the higher binding affinity of **39e** compared to **39d** followed by **39b**.

(vi) Glycogen synthase kinase 3 (GSK-3) inhibitors

Glycogen synthase kinase-3 (GSK-3) inhibitors are a class of serine/threonine kinases and classified further into the GSK-3 α and GSK-3 β forms.⁷⁷ Further, GSK can act as a tumor suppressor in many cancer types such as lung,^{78,79} breast,⁸⁰⁻⁸² skin,^{83,84} pancreas,⁸⁵⁻⁸⁸ hepatocellular carcinoma^{89,90} and leukemia.^{91,92} However, to date, no USFDA-approved GSK inhibitor is available in the market for the treatment of cancer.

Prati *et al.* reported the structure–activity relationship of compounds (**41–44**) derived from **40** *via* the introduction of

different groups around the *1H*-indazole-3-carboxamide scaffold for improving GSK selectivity (Fig. 16).⁹³ Their studies suggested that the replacement of the (2-methoxyethyl)-4-methylpiperidine group by oxanyl, oxolanyl, thiolanedionyl and thianedionyl groups reduced the lipophilicity of the resultant derivatives (**33–41**) and led to improved selectivity towards the human ether- α -go-go-related dene (hERG) by 41–500 fold compared to compound **40**. Further, replacement of the difluorophenyl moiety with polar pyridinyl and alkoxy-substituted pyridinyl groups led to compounds (**44a–f**) with promising activities (hERG $\text{IC}_{50} > 40 \mu\text{M}$), except for compounds **44b** and **44c** (hERG $\text{IC}_{50} = 0.86$ and $5.70 \mu\text{M}$, respectively). Compound **44d** emerged as the most promising compound with excellent activity (GSK-3 β ; $\text{IC}_{50} = 0.004 \mu\text{M}$ and hERG; $\text{IC}_{50} > 100 \mu\text{M}$).




Fig. 16 Indazole derivatives with improved GSK selectivity.






Fig. 17 1*H*-Indazole-3-carboxamide derivatives as potential inhibitors of human GSK-3.

Ombrato *et al.* reported the structure-based discovery of 1*H*-indazole-3-carboxamide derivatives (Fig. 17) as potential inhibitors of human GSK-3.⁹⁴ These compounds were found to bind to the ATP binding site of GSK-3 β . Substitution of the amine group with dimethylamine did not lead to any improvement in activity (47 and 8). The activity of compound 48 with a methyl group at the 5-position of the indazole ring was found to be lower than that of methoxy derivatives 49 (IC₅₀ = 1.7 μ M) and 50 (IC₅₀ = 0.35 μ M), suggesting the importance of this group for high potency. The addition of a methyl group on the indazole phenyl ring of 45 (IC₅₀ = 3.0 μ M) led to a remarkable increase in activity (46, IC₅₀ = 0.64 μ M).

Furlotti *et al.* reported 5-substituted-*N*-(piperidin-4-ylmethyl)-1*H*-indazole-3-carboxamide derivatives (Fig. 18) as glycogen synthase kinase-3 (GSK-3) inhibitors.⁹⁵ Replacement of the methyl group on the piperidine ring of 51a (IC₅₀ = 1.20 μ M) with *N*-alkylcarboxylic acid led to an increase in activity (51b, 51c and 51d; IC₅₀ = 0.67, 0.69 and 0.23 μ M, respectively), whereas the introduction of a terminal polar group did not alter its activity (51e and 51f; IC₅₀ = 0.87 and 1 μ M, respectively). Interestingly, carboxylic acid derivatives 51g and 51h exhibited remarkable activity of 0.07 and 0.05 μ M, respectively. Further optimization led to 2,3-difluorophenyl derivative 51j with IC₅₀ = 18 nM, whereas the 2-methyl derivative (51i) and 4-methoxy phenyl derivatives (51k and 51l) exhibited poor activity. Further studies showed that 51j exhibited good *in vivo* PK activity and was found to be selective against only 34 kinases with more than 50% inhibition in a study for 216 kinases.

(vii) Aurora kinase (AURK) inhibitors

Aurora kinases (AURKs) are a class of serine/threonine kinases, which can further be classified into AURKA, AURKB and AURKC.⁹⁶ Overexpression of the aurora kinases has been observed in many cancer types such as breast cancer,^{97–100} gastrointestinal cancer,^{101,102} ovarian cancer^{103–105} and other




Fig. 18 5-Substituted-*N*-(piperidin-4-ylmethyl)-1*H*-indazole-3-carboxamide as glycogen synthase kinase-3 (GSK-3) inhibitors.




Fig. 19 Novel indazole derivatives as inhibitors of Aurora kinases.






Fig. 20 Docking studies of **53d** with Aurora A (PDB ID: 2W1C). Green lines represent hydrogen bonding and red lines represent hydrophobic interactions (reproduced with permission; License Number: 5087990401536).




Fig. 21 Docking studies of **53f** with Aurora B (PDB ID: 4C2V). Green lines represent hydrogen bonding and red lines represent hydrophobic interactions (reproduced with permission; License Number: 5087990401536).

tumors,^{106–108} thereby making these kinases important therapeutic targets to develop selective anticancer agents.

Chang *et al.* reported novel amide derivatives of indazole as inhibitors (Fig. 19) of Aurora kinases.¹⁰⁹ Compound **52a** was screened as the initial hit with an IC_{50} value of 13 μM . Introduction of an acryloyl moiety enhanced the kinase activity of the resulting compounds (**52b** and **52c** with IC_{50} = 1.66 and 0.79 μM , respectively), whereas the ethylamide derivative (**52d**) was found to be inactive. Substitution of indazole at the C5 or C6 position with phenyl urea (**53a**), phenyl amide (**53b**) and benzylamine (**53c**) resulted in either the same or better activity with IC_{50} < 1 μM . Interestingly, the C5-substituted sulfonamide derivative (**53d**) exhibited remarkable activity (IC_{50} = 26 nM). Further substitution of the phenylsulfonyl group with methyl (**53e**), methoxy (**53f**) and nitro (**53g**) groups resulted in equipotent derivatives, whereas substitution with a bulkier group led to a decrease in activity.

The molecular docking analysis of **53d** suggested the binding of indazole with hinge residues of Glu211 and Ala213, whereas the sulfonyl group formed a hydrogen bond with Lys141, which contributed its significant potency against Aurora A. In addition, the carboxylic acid of **53d** formed a hydrogen bond with Thr217 and Arg220 (Fig. 20). Conversely, the methoxy group of **53f** (Fig. 21) offered steric hindrance to Asp274 in the back pocket of Aurora A, resulting in lower activity.

Song *et al.* reported 3-(pyrrolopyridin-2-yl)indazole derivatives (Fig. 22) as inhibitors of aurora kinase A.¹¹⁰ The synthesized compounds were studied against a human hepatocarcinoma cancer cell line (SMMC-7721), human colorectal carcinoma cancer cell line (HCT116), human lung carcinoma cancer cell line (A549), and human leukemia cancer cell line (HL60). Besides urea derivatives **55a** and **55b**, which showed remarkable activities (IC_{50} = 0.0083–1.43 μM), all the other compounds were active against the tested cell lines with moderate potency. The introduction of electron-donating groups (**54e**; IC_{50} = 3.32–29.47 μM and **54f**; IC_{50} = 1.42–22 μM) and electron-withdrawing group (**54g**, IC_{50} = 6.80–34.47 μM)

μM) led to a decrease in overall potency. Further studies on **54a**, **54c** and **55a** against a set of 8 kinases suggested that these compounds act as inhibitors of Aurora kinase A with IC_{50} = 32, 46 and 519 nM, respectively, emphasizing the requirement of a halogen atom for enhanced potency. These studies were further supported by a docking study.


Fig. 23 depicts the binding mode of **54a** and **55a** with Aurora kinase A. Both derivatives occupied the ATP binding site of Aurora kinase A, where the binding was significantly stabilized by hydrogen bonding with the hinge backbone of Ala213 and Glu211. The amide and urea linkage of **54a** and **55a** facilitated the orientation of the phenyl ring towards the solvent, respectively.

(viii) pan-Pim inhibitors

pan-Pim kinases belong to the serine/threonine kinase family, which are further classified into three members including Pim-1, Pim-2 and Pim-3. Overexpression of these kinases is associated with various crucial processes such as cell proliferation, survival and differentiation.¹¹¹ The expression level of Pim kinases varies based on the tumor type.¹¹² An increase in Pim-1 and Pim-3 levels is a predictor of poor prognosis in gastric cancer.^{113,114}


Hu *et al.* discovered 3,5-substituted-6-azaindazoles as inhibitors (Fig. 24) of pan-Pim kinase.¹¹⁵ The introduction of a methyl group at the C3-position of the azaindazole ring resulted in a 6-fold increase in the potency of compound **56a** (K_i = 1.3–6 μM) to compound **56b** (K_i = 0.2–0.8 μM) against Pim-1, Pim-2 and Pim-3. The presence of N6 in compound **56c** resulted in 3–10-fold potency (K_i = 0.3–0.9 μM) as compared to compound **56d** (K_i = 2.7–3.2 μM). Interestingly, replacement with a phenyl or pyridin-2-yl group resulted in a remarkable increase in potency (**56e**; K_i = 0.005–0.5 μM and **56f**; K_i = 0.01–0.07 μM), respectively. Substitution at the C-3 position of the azaindazole ring with five- or six-membered heterocyclic rings (**57a–d** and **58a–c**) led to moderate potency, respectively. Compound **58d** exhibited the most balanced potency (K_i = 0.041–0.73 μM) and stability *in vivo*.





54a. $R_1 = \text{Ph}$, $R_2 = \text{H}$
54b. $R_1 = 4\text{-F-Ph}$, $R_2 = \text{H}$
54c. $R_1 = 4\text{-Cl-Ph}$, $R_2 = \text{H}$
54d. $R_1 = 4\text{-Br-Ph}$, $R_2 = \text{H}$

54e. $R_1 = 4\text{-CH}_3\text{OMe-Ph}$, $R_2 = \text{H}$
54f. $R_1 = 3\text{-CH}_3\text{OMe-Ph}$, $R_2 = \text{H}$
54g. $R_1 = 4\text{-NO}_2\text{-Ph}$, $R_2 = \text{H}$
54h. $R_1 = \text{Ph}$, $R_2 = \text{-CN}$



55a. $R_1 = \text{Ph}$, $X = \text{-NH-CO-}$
55b. $R_1 = 4\text{-CH}_3\text{OMe-}$, $X = \text{H}$

Fig. 22 3-(Pyrrolopyridin-2-yl)indazole derivatives as inhibitors of Aurora kinase A.




Fig. 23 (A) Docking study of 54a with Aurora kinase A (reproduced with permission; License Number: 5087590256958). (B). Docking study of 55a with Aurora kinase A (reproduced with permission; License Number: 5087590256958).

Wang *et al.* reported 3-(pyrazin-2-yl)-1*H*-indazole derivatives (Fig. 25) as potential inhibitors of pan-Pim kinase.¹¹⁶ Compound 59a showed good potency (Pim1-3, $IC_{50} = 3\text{--}11 \text{ nM}$) but lacked metabolic stability, whereas compound 59b

exhibited good metabolic stability but moderate potency (Pim1-3, $IC_{50} = 142 \geq 3000 \text{ nM}$). Replacement of the piperidine moiety of 2 with 2-aminopiperidine led to compound 59c with nanomolar potency (Pim1-3, $IC_{50} = 3\text{--}70 \text{ nM}$). Replacement of 3-




Fig. 24 3,5-Disubstituted 6-azaindazoles as inhibitors of pan-Pim.






Fig. 25 3-(Pyrazin-2-yl)-1H-indazole derivatives as potential inhibitors of pan-Pim kinase.




Fig. 26 (3-Aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one derivatives as PLK4 inhibitors.

aminopiperidine with 4-piperidine led to a further improvement in activity (**60a**; $IC_{50} = 1\text{--}9\text{ nM}$), whereas replacement of the amine group with hydroxyl led to a decrease in activity (**60b**; $IC_{50} = 44\text{--}362\text{ nM}$). Interestingly, the spirocyclopropyl analogue (**S-60e**) exhibited remarkable activity ($IC_{50} = 0.4\text{--}1.1\text{ nM}$);

however, moderate cellular potency against a human myeloma cancer cell line (KMS-12 BM) ($IC_{50} = 1400\text{ nM}$). Further, the removal of fluorine atoms from **60e** led to a decrease in cellular potency ($IC_{50} = 1970$ and 3400 nM for **61a** and **61b**, respectively). Interestingly, the introduction of polar groups at the C4




Fig. 27 N-substituted prolinamido indazole derivatives as potent Rho-kinase inhibitors.






Fig. 28 Proposed docking of **67** with the ATP binding pocket of ROCK1 (reproduced with permission)

position of 2-fluorophenyl ring led to improved cellular potency (**61c–g**; KMS-12 BM, $IC_{50} = 120\text{--}30\text{ nM}$), while retaining enzyme activity.

(ix) Plo-like kinase 4 (PLK4) inhibitors

Plo-like kinase 4 (PLK4) is a family of tyrosine serine/threonine kinases that play an important role in cell regulation and cellular response.^{117,118} An abnormal level of PLK4 results in

tumorigenesis and centriole amplification and is further associated with several human cancers.^{119–121}

Li *et al.* reported (3-aryl-1*H*-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-one derivatives (Fig. 26) as PLK4 inhibitors.¹²² The pyridin-3-yl analogue of the lead compound **62a** possessed 10-fold potency (**62b**, $IC_{50} = 0.029 \mu\text{M}$ and $0.027 \mu\text{M}$ against PLK4 and fms-like tyrosine kinase 3 (FLT3) *versus* **62a**, $IC_{50} = 0.29$ and $0.049 \mu\text{M}$, respectively). Further, (4-methylpiperazin-1-yl)pyridin-3-yl (**62c**, $IC_{50} = 0.029 \mu\text{M}$ and $0.027 \mu\text{M}$ against PLK4 and FLT3, respectively) and the methoxy derivative of **4f** (**62d**, $IC_{50} = 0.0024 \mu\text{M}$ and $0.028 \mu\text{M}$ against PLK4 and FLT3, respectively) showed significantly enhanced activity. Optimization of **62c** led to compound **63a**, which exhibited activity against FGFR in the nanomolar range ($IC_{50} = 0.0010 \text{ nM}$) with 2-fold selectivity over FLT3 ($IC_{50} = 0.26$). Further optimization led to **64a** and **64b** having aryl substitution, which showed better activity compared to their vinyl counterpart **62c**. Interestingly, among the 274 kinases studied, **64b** was found to be selective to only 15 kinases with more than 50% inhibition.

(x) Rho-associated coiled-coil kinase (ROCK) inhibitors

Rho-associated coiled-coil kinases (ROCKs) belong to the AGC family of serine/threonine protein kinases, which include ROCK1 and ROCK2. These play important roles in many cellular reactions such as cell proliferation, contraction, migration,




Fig. 29 3-Carboxamido-2*H*-indazole-6-arylamide derivatives as selective CRAF inhibitors.




Fig. 30 Docking structures of **71a** with CRAF (3OMV) and BRAF V599E (reproduced with permission; License Number: 5087580376405).

adhesion and apoptosis,^{123–125} and therefore can be used as potential targets for cancer management.¹²⁶

Yao *et al.* reported N-substituted prolinamido indazole derivatives (Fig. 27) as potent Rho-kinase inhibitors.¹²⁷ The SAR studies indicated that derivatives with a β -proline moiety (**67** and **68**) having linear-shaped compounds possessed enhanced activity against ROCK I compared to the angular-shaped derivatives bearing an α -proline moiety (**65** and **66**). In the benzyl-substituted series (**67**), the substituent effect on the activity followed the order of $\text{CH}_3 > \text{H} > \text{Br} > \text{OCH}_3 > \text{F} > \text{NO}_2, \text{CN}$. Further, the S-isomer (**67a**, $\text{IC}_{50} = 0.42 \mu\text{M}$) showed better activity than the R-isomer (**67b**, $\text{IC}_{50} = 7.32 \mu\text{M}$). Conversely, the R- and S-isomers exhibited similar activity in the case of **65** (**65a**, % inhibition = 24.3% vs. **65b**, % inhibition = 24.6%) and **66** (**66a**, % inhibition = 15.0% vs. **66b**, % inhibition = 23.7%).

The racemic mixture of **67** was also studied for its docking with ROCK1, which suggested hydrogen bond interactions between the N and NH of indazole with Met156. In addition, the terminal phenyl ring was also observed to participate in π -cation interactions with Lys105 (Fig. 28).

(xi) CRAF inhibitors

CRAF belongs to the family of RAF kinases family of serine/threonine-specific kinases. It has been reported to play a role in oncogenic human cancers.^{128,129}

Aman *et al.* reported 3-carboxamido-2*H*-indazole-6-arylamide derivatives (Fig. 29) as selective CRAF inhibitors.¹³⁰ 1,3,4-Substituted benzoic acid analogues with an amide linker exhibited good activity against human melanoma cell lines (WM3629 and A375P) ($\text{GI}_{50} = 9.13$ and $7.37 \mu\text{M}$ and 10.5 and $28.3 \mu\text{M}$ for **69a** and **69b**, respectively, *versus* $\text{GI}_{50} = 30 \mu\text{M}$ for **69c**). A similar trend was observed for 1,3,4-substituted benzoic acid derivatives with a urea linker (**70a**, $\text{GI}_{50} = 3.51$ and $10.05 \mu\text{M}$ *versus* **70b**, $\text{GI}_{50} = 9.29$ and $12.3 \mu\text{M}$, respectively). Further optimization led to the discovery of bulkier and longer analogs **71a** and **71b** with remarkable activity ($\text{GI}_{50} = 0.65$ and $2.25 \mu\text{M}$ and 15.93 and $25.6 \mu\text{M}$ for **71a** and **71b**, against WM3629 and A375P, respectively). Moreover, **71a** exhibited 35-fold higher activity against the WM3629 cell line and was found to be a selective CRAF inhibitor with an excellent selectivity profile and 99% inhibitory activity against CRAF as compared to 20% inhibitory activity against other kinases in the study with 32 kinases.

These observations were further supported by the docking studies of **71a** on CRAF (3OMV) and BRAF V599E (PDB Code: 1UWJ) (Fig. 30). These studies suggested that **71a** was tightly bound to CRAF kinase with the formation of two hydrogen bonds of the nitrogen atoms of indazole and hinge residue Cys424. Two additional hydrogen bonds were also observed with the hinge residue of Trp423 and Lys431. In addition, a hydrogen bond between the amide of **71a** bond and Ser357, π - π interaction between indazole and Trp423 and π -cation interactions between indazole and Lys470 were also observed. Conversely, only two hydrogen bond interactions of indazole with Gly533 and Ser 601 were possible in the case of the docking studies of **71a** with BRAF V599E.




Fig. 31 Galloyl benzamide-based indazole modulator of MAPK signaling pathways.

(xii) Mitogen-activated protein kinase (MAPK) inhibitors

Mitogen-activated protein kinases (MAPKs) belong to the family of serine/threonine-specific protein kinases, which play a crucial role in cell growth, proliferation and survival.^{131,132}

Leo *et al.* studied the effect of galloyl benzamide-based indazole derivatives (Fig. 31) on the MAPK signaling pathways in comparison to adenosine triphosphate (ATP)-competitive JNK inhibitor SP600125.¹³³ Compound 72 was observed to be a poor inhibitor of P-gp and MRP1. Pretreatment with 72 at 1, 20 and 50 μM resulted in the inhibition of TNF- α -mediated phosphorylation of JNK, which was comparable to SP600125 at 20 μM and inhibited TNF- α -mediated p38 MAPK phosphorylation at high concentrations. A similar trend was also observed for the inhibition of the TNF- α -mediated phosphorylation of c-Jun N-terminal kinase, whereas no significant inhibition was observed in the case of ERK1/2, NF- κ B for compound 72.

(xiii) Janus kinase (JAK) inhibitors

The Human JAK family can be classified into 4 members including JAK1, JAK2, JAK3 and Tyk2.^{134,135} JAK2 is known to mediate important physiological functions such as cell proliferation.^{136,137} Overexpression of JAK3 is also associated with juvenile myelomonocytic leukemia.¹³⁸ Tofacitinib was the first approved JAK inhibitor, after which various JAK inhibitors were developed.

Ritzen *et al.* reported 6-arylindazole derivatives (Fig. 32) as JAK inhibitors.¹³⁹ The introduction of a phenolic group in indazolo fragment **73** led to an increase in potency in **74a** ($\text{pIC}_{50} = 5.4$ *versus* 4.5). Replacement of the methylsulfonamide group with ethylsulfonamide led to a further increase in potency (**74b**, $\text{pIC}_{50} = 5.7$). Substitution of R_2 with a small lipophilic group (**74c** and **e**) resulted in enhanced cellular potency, with **74d** being the most active. Substitution at R_3 with a halogen or alkoxy group (**74f**–**74i**) led to a slight increase in cellular potency with the halide analogs (**74g**–**h**) showing highest the potency in the group. Further optimization led to the discovery of **74i**–**j**, with **74k** as the most active compound in the series ($\text{pIC}_{50} = 6.77$) with good LLE values.




Fig. 32 6-Arylindazole derivatives as JAK inhibitors.

Derivative 74a was subjected to docking studies with JAK2, which suggested hydrogen bonding with Leu932 and Glu930. Further, additional hydrogen bonding was observed for the phenol group with α C helix residue Glu898 and NH group of Phe995. Also, the phenol group was found to be in contact with Met929 (Fig. 33).

Bajusz *et al.* reported the structure-based virtual screening of indazole derivatives (Fig. 34) as potential inhibitors of Janus kinase (JAK).¹⁴⁰ The screened compounds 76 and 77 were found to be selective to the JAK2 subtype compared to the JAK1 subtype. Compound 77 exhibited remarkable activity against JAK2 ($\text{IC}_{50} = 2.38 \mu\text{M}$) compared to JAK1 ($\text{IC}_{50} = 33 \mu\text{M}$), whereas compound 76 exhibited $\text{IC}_{50} = 5.72 \mu\text{M}$ with only 1% inhibition of JAK1 at $20 \mu\text{M}$. Further, docking studies supported that the tetrazole ring of 77 was buried deep in the binding pocket of JAK2, whereas it is exposed towards the solvent in the case of JAK1.

(xiv) Melanin-concentrating hormone receptor 1 (MCHR1) inhibitors

Melanin-concentrating hormone receptor 1 is reported to activate extracellular signal-regulated kinase pathways.¹⁴¹

Igawa *et al.* reported 1-(2*H*-indazole-5-yl)pyridin-2(1*H*)-one derivatives (Fig. 35) as melanin-concentrating hormone receptor 1 (MCHR1) antagonists.¹⁴² The structure–activity relationship (SAR) studies revealed that the 2,4-disubstituted thiophene derivatives (78c and d) were more potent than the 2,5-disubstituted thiophene (78b) and thiazole derivatives (78e and f). Interestingly, the 2-cyclopropylindazole derivatives (78j–l) possessed better activity than the methyl analogs (78a, 78g and 78d). Also, 78j ($\text{IC}_{50} = 33 \text{ nM}$) and 78l ($\text{IC}_{50} = 79 \text{ nM}$) were found to have the best *in vitro* potency and did not include the risk of mutagenesis. Derivative 78l also exhibited a superior anorectic effect in the *in vivo* studies and possessed good brain exposure.




Fig. 33 Proposed docking of 74a with JAK2 (reproduced with permission).






Fig. 34 Structure-based virtual screening of indazole derivatives as potential inhibitors of Janus kinase (JAK).

(xv) G protein-coupled receptor kinase 2 (GRK2) inhibitors

G protein-coupled receptor kinases (GRKs) are known to act as negative regulators of G protein-coupled receptors (GPCR) activity, and therefore play a crucial role in cell progression by controlling various physiological reactions such as cell proliferation, invasion, migration, apoptosis and tumor vascularization.¹⁴³⁻¹⁴⁵

Bouley *et al.* reported the activity of indazole-paroxetine hybrids (Fig. 36) against G protein-coupled receptor kinase 2 (GRK2).¹⁴⁶ Compound 79a exhibited 20-times greater potency ($IC_{50} = 66$ nM) than paroxetine (79b; $IC_{50} = 1.38$ μ M) against GRK2 with an increase in the activity of 79a against GRK1, 5PKA, and ROCK1 and decrease in selectivity (5-fold) against ROCK1 compared to paroxetine (50-fold). The introduction of the 2,6-dimethoxybenzylamide group on fluorophenyl C-ring (79c) resulted in increased selectivity against GRK2 compared to other GRK and PKAs. Interestingly, the introduction of the 3-pyrazolylmethylamide group induced 79e, which was most the effective against GRK2 with an IC_{50} value of 8 nM and selective (20-fold) for other GRKs and PKAs. Conversely, *N*-methylation of

the pyridine ring (79b) led to a decrease in potency against GRK1, GRK5 and PKA.

(xvi) Extracellular signal-regulated kinase (ERK) inhibitors

Activation of the extracellular signal-regulated kinase (ERK) pathway is well known to contribute to various types of cancers.^{147,148} Therefore, inhibition of the ERK pathway can play a crucial role in cancer treatment.

Li *et al.* reported indazole amide derivatives (Fig. 37) as inhibitors of extracellular signal-regulated kinase 1/2 (ERK1/2).¹⁴⁹ Substitution of the lead compound 80a ($IC_{50} = 63.3$ nM) with nitrogen led to a decrease in activity (80b, $IC_{50} = 139.5$ nM), while replacement with carbon showed a positive effect (80c; ERK2, $IC_{50} = 33.8$ nM). Substitution of the phenyl ring with chlorine, and further shortening of the side chain resulted in 80d with $IC_{50} = 12.6$ nM. Interestingly, the S-isomer hydroxymethyl analogue (S-81a) exhibited remarkable activity ($IC_{50} = 7.0$ nM). Further, the introduction of pyridine at the benzylic position led to good enzyme activity with remarkable cellular activity (ERK2, $IC_{50} = 16.7, 7.9, 13.2$ nM and HT-29, $IC_{50} = 0.35, 1.1, 0.713$ nM for 83a, 83c and 83d, respectively). Further




Fig. 35 1-(2H-Indazole-5-yl)pyridin-2(1H)-one derivatives as MCHR1 antagonists.






Fig. 36 Indazole-paroxetine hybrids as G protein-coupled receptor kinase 2 inhibitors.

S-83b (ERK2, $IC_{50} = 9.5$ nM and HT-29, $IC_{50} = 10.7$) showed better enzyme activity but lower cellular activity than the R-isomer and racemate counterpart (**83a**).

(xvii) Unc-51-like kinase 1 (ULK-1) inhibitors

Unc-51-like kinase 1 (ULK-1) is a cytoplasmic kinase that is involved in the autophagy process. It can either promote or inhibit tumor growth,¹⁵⁰ and therefore either positive or negative regulation of ULK-1 can lead to cancer management.¹⁵¹

Wood *et al.* reported the *in silico* HTS and structure-based optimization of indazole derivatives (Fig. 38) as ULK-1 inhibitors.¹⁵² Initial screening led to the discovery of SR-17398 with ULK-1 with the IC_{50} value of 22.4 μ M. Substitution by an amino group at the 3-position of the indazole ring afforded **84a** with ULK-1, $IC_{50} = 368$ nM. Further, replacement of the cyclohexyl group with a 3-aminohexyl (**84b**) or 3-aminopropyl group (**84c**) led to a decrease in activity (ULK-1, $IC_{50} = 18.1$ μ M and >33 μ M), while piperidine substitution gave reasonable activity (**84d**, ULK-1, $IC_{50} = 560$ nM). Substitution with a naphthyl ring resulted in a significant enhancement in activity (ULK-1, $IC_{50} =$




Fig. 37 Indazole amide derivatives as inhibitors of extracellular signal-regulated kinase 1/2 (ERK1/2).





Fig. 38 *In silico* HTS and structure-based optimization of indazole derivatives as ULK-1 inhibitors.



Fig. 39 $1H$ -Indazole-3-carboxamide derivatives as inhibitors of PAK1.

11 nM), whereas the quinoline derivatives (**85c** and **85d**) possessed lower activity than **86a**. The *cis*-isomers (**86b** and **86c**, ULK-1, $IC_{50} = 3$ and 45 μM , respectively) were found to be less active than the *trans*-isomer (**86d**, ULK-1, $IC_{50} = 24$ nM).

(xviii) P21-activated kinase (PAK1) inhibitors

P21-activated kinases (PAKs) belong to the non-receptor serine/threonine protein kinase family, which play an important role in many signaling pathways, and thus contribute to cancer development.¹⁵³ They can be classified into two groups, where group-I includes PAK1-3 and group-II includes PAK4-6.¹⁵⁴ Abnormal expression of PAK1 is associated with skin cancer,¹⁵⁵⁻¹⁵⁷ breast cancer¹⁵⁸ and pancreatic cancer.¹⁵⁹




Fig. 40 Truncated indazole derivatives as leucine-rich repeat kinase 2 (LRRK2) inhibitors.

Zhang *et al.* reported $1H$ -indazole-3-carboxamide derivatives (Fig. 39) as inhibitors of PAK1.¹⁶⁰ Initial screening of 235 molecules resulted in compound **87a** (PAK1, $IC_{50} = 5 \mu\text{M}$), which was further utilized for scaffold modification. Introducing a hydrophobic moiety onto the chlorophenyl group led to derivatives with enhanced activity against PAK1 (**87b**; $IC_{50} = 159$ nM, **87c**; $IC_{50} = 52$ nM and **87d**; $IC_{50} = 16$ nM). Interestingly, compound **88f** was found to be 1000-fold more active against PAK1 compared to PAK4 and was selective in the presence of other 28 kinases. It also displayed low hERG channel activity and was found to decrease the invasion of HCT116 and MDA-MB-231 cancer cells.




Fig. 41 Indazole-substituted morpholino-triazines as PI3 kinase inhibitors.



(xix) Leucine-rich repeat kinase 2 (LRRK2) inhibitors

Leucine-rich repeat kinase 2 (LRRKs2) belongs to the leucine-rich repeat kinase family and overexpression of LRRK2 is related to the inhibition of proliferation and migration of cellular events related to thyroid cancer.^{161,162}

Scott *et al.* reported truncated indazole derivatives (Fig. 40) as leucine-rich repeat kinase 2 (LRRK2) inhibitors and compared their activity with reference to compounds **89** and **90** ($IC_{50} = 44$ and 728 nM, respectively), which were the results of initial high throughput screening of a library of compounds.¹⁶³ Thus, the 3- and 4-pyridyl analogs (**91a** and **91b**; $IC_{50} = 904$ and





Fig. 42 3-(4-(heterocyclic)phenyl)-1*H*-indazole-5-carboxamide derivatives as tyrosine threonine kinase (TTK) inhibitors.





96a. R = 2-fluoro-3-methoxyphenyl; **96b.** R = 3-methoxyphenyl
96c. R = 3-ethoxyphenyl; **96d.** R = 3-isopropoxyphenyl
96e. R = 3-oxypropylphenyl; **96f.** R = 4-methoxyphenyl
96g. R = 4-(trifluoromethyl)phenyl; **96h.** R = 4-chlorophenyl

Fig. 43 Indazole derivatives as dual inhibitors of FGFR1 and HADC.




Fig. 44 (a) Docking mode of compound **96c** with HDAC6 (reproduced with permission; License Number: 5090111285759). (b) Docking mode of compound **96e** with HDAC6 (reproduced with permission; License Number: 5090111285759). (c) Superposed docking poses of **96c** (green) and **96e** (blue) with HDAC6 (reproduced with permission; License Number: 5090111285759).


1231 nM, respectively) were found to be more potent than the 2-pyridyl analog (**91c**; $IC_{50} = 6186$ nM). Further, substitution of the pyridyl ring with the piperazine moiety significantly enhanced the activity (**91d**; $IC_{50} = 12$ nM), which was 21-fold more than regioisomer **91e** ($IC_{50} = 256$ nM) and 11-fold more than **91f** ($IC_{50} = 134$ nM). Interestingly, the introduction of a pyrazole group at C5 led to a series of highly potent compound **91g** with $IC_{50} < 0.6$ nM. Compound **91h** with an isopropoxy

substituent possessed high activity ($IC_{50} = 7$ nM) with excellent selectivity (17 out of 306 kinases studied).

(xx) Phosphatidylinositol-3-kinase (PI3K) inhibitors

Phosphatidylinositol-3-kinases are a family of enzymes that are responsible for the regulation of cell growth, angiogenesis, metabolism, motility and survival.^{164,165} Dysregulation of the PI3K pathway leads to colorectal and breast cancer and





97a. $R_1 = R_2 = H$, $X = C$;

97c. $R_1 = H$, $R_2 = 4\text{-F}$, $X = C$;

97e. $R_1 = H$, $R_2 = 4\text{-Me}$, $X = C$;

97g. $R_1 = \text{OMe}$, $R_2 = 4\text{-OMe}$, $X = C$;

97i. $R_1 = \text{OMe}$, $R_2 = 4\text{-Cl}$, $X = C$;

97k. $R_1 = R_2 = H$, $X = O$;

97m. $R_1 = H$, $R_2 = 4\text{-F}$, $X = O$;

97o. $R_1 = H$, $R_2 = 4\text{-Me}$, $X = O$;

97q. $R_1 = \text{Me}$, $R_2 = 4\text{-OMe}$, $X = O$;

97s. $R_1 = \text{Me}$, $R_2 = 4\text{-Cl}$, $X = O$;

97b. $R_1 = H$, $R_2 = 4\text{-OMe}$, $X = C$;

97d. $R_1 = H$, $R_2 = 4\text{-Cl}$, $X = C$;

97f. $R_1 = \text{OMe}$, $R_2 = H$, $X = C$;

97h. $R_1 = \text{OMe}$, $R_2 = 4\text{-F}$, $X = C$;

97j. $R_1 = \text{OMe}$, $R_2 = 4\text{-Me}$, $X = C$;

97l. $R_1 = H$, $R_2 = 4\text{-OMe}$, $X = O$;

97n. $R_1 = H$, $R_2 = 4\text{-Cl}$, $X = O$;

97p. $R_1 = \text{Me}$, $R_2 = H$, $X = O$;

97r. $R_1 = \text{Me}$, $R_2 = 4\text{-F}$, $X = O$;

97t. $R_1 = \text{Me}$, $R_2 = 4\text{-Me}$, $X = O$;

Fig. 45 3a,4,5-Tetrahydro-2H-benzo[g] indazole derivatives of quinoxaline as EGFR/HER-2 dual inhibitors.

hematologic malignancies.¹⁶⁶ Therefore, inhibition of PI3K is associated with the suppression of cellular proliferation and enhancement of cellular death.¹⁶⁷

Dugar *et al.* reported indazole-substituted morpholino-triazines (Fig. 41) as PI3 kinase inhibitors.¹⁶⁸ The lead compound 92a ($\text{IC}_{50} = 1.10 \mu\text{M}$) was used as a starting point for

further optimization. Replacement of the glycine amide chain with a conformational restricted 6- or 7-membered ring led to an improvement in cellular and antiproliferation activity (92b; PI3, $\text{IC}_{50} = 0.40 \mu\text{M}$; A2780, $\text{IC}_{50} = 3.97 \mu\text{M}$ and 92c, PI3, $\text{IC}_{50} = 0.20 \mu\text{M}$; and A2780, $\text{IC}_{50} = 2.64 \mu\text{M}$). Further optimization of the spacer and orientation of the terminal amide led to compounds 92d–g with enhanced activity. Interestingly compound 92h with *para*-substitution of the amide group exhibited remarkable activity (PI3, $\text{IC}_{50} = 0.06 \mu\text{M}$ and A2780, $\text{IC}_{50} = 0.52 \mu\text{M}$). Further, compounds 92h–j did not show any inhibition of CYP3A4, CYP2C19 and CYP2D6 and were not predicted to have any hERG liability.

(xi) Tyrosine threonine kinase (TTK) inhibitors

Tyrosine threonine kinase (TTK) is a dual-specific kinase with upregulation found in different type of cancers such as breast cancer, anaplastic thyroid carcinoma (ATC), pancreatic ductal adenocarcinoma (PDAC) and human hepatocellular carcinoma (HCC), and therefore, inhibition of TTK results in the inhibition of cell growth and enhancement of cell apoptosis.^{169–172}

Liu *et al.* reported 3-(4-(heterocyclic)phenyl)-1*H*-indazole-5-carboxamide derivatives (Fig. 42) as tyrosine threonine kinase (TTK) inhibitors.¹⁷³ Modification of sulfonamide (93a, $\text{IC}_{50} = 0.0029 \mu\text{M}$) to a sulfone derivative (93b, $\text{IC}_{50} = 0.0059 \mu\text{M}$) was well tolerated, but a reduction in the polar surface area (93c, $\text{IC}_{50} = 0.018 \mu\text{M}$) led to a 4-fold decrease in potency. Also, 4-




Fig. 46 (A) Predicted binding model of 97g with EGFR (reproduced with permission). (B) Surface of the binding site of 97g with EGFR (reproduced with permission).






Fig. 47 (A) Predicted binding model of 97r with EGFR (reproduced with permission). (B) Surface of the binding site of 97r with EGFR (reproduced with permission).





98a. X = SO, R₁ = H, R₂ = 2-fluoro-5-chlorophenyl
98b. X = SO, R₁ = H, R₂ = 2,3-dichlorophenyl
98c. X = C, R₁ = H, R₂ = 2-fluoro-5-chlorophenyl
98d. X = C, R₁ = OMe, R₂ = 2-fluoro-5-chlorophenyl
98e. X = SO, R₁ = OH, 2-fluoro-5-chlorophenyl
98f. X = SO, R₁ = OH, R₂ = 2,3-dichlorophenyl



99a. X = SO, R₁ = H, R₂ = 2,3-dichlorophenyl
99b. X = SO, R₁ = OH, R₂ = Me
99c. X = SO, R₁ = OH, R₂ = Ph
99d. X = C, R₁ = OH, R₂ = 2-fluoro-5-chlorophenyl
99e. X = C, R₁ = OH, R₂ = 2,3-dichlorophenyl

Fig. 48 2H-Indazoles derivatives as potential inhibitors of SGK1, Tie2 and SRC.

monosubstituted derivatives (**93d-g**) exhibited acceptable TTK activity ($IC_{50} = 0.003\text{--}0.007\ \mu\text{M}$) together with good cell viability ($GI_{50} < 0.057\ \mu\text{M}$). Further optimization led to carboxamide analogs with different heterocyclic moieties (**94a** and **b**, and **94c-e**) with TTK IC_{50} in the nano molar range. Further, the bridged formylated derivatives **95d-g** retained potency, among which **95g** (TTK, $IC_{50} = 0.0011\ \mu\text{M}$ and AURKB/INCENP, $IC_{50} = 0.80\ \mu\text{M}$) retained potency and selectivity against AURKB/INCENP. Further optimization led to the discovery of **95h**, showing good activity (TTK, $IC_{50} = 0.0012\ \mu\text{M}$; HCT116 and $GI_{50} = 0.003\ \mu\text{M}$) and high selectivity over AURKB/INCENP. Further studies suggested that compound **95i** has potency of $K_i = 0.7\ \text{nM}$ and was found to be selective against a panel of 278 human kinases including the mutant form of cKit, Ret, c-Jun N-terminal kinase 3 (JNK3), PLK4 and mitogen-activated protein kinase 2 (MAPK2) compared to sunitinib.

3. Multiple kinase inhibitors

(i) Fibroblast growth factor receptor-1 (FGFR1) and histone deacetylase (HDAC) inhibitors

Liu *et al.* reported a series of indazole derivatives (Fig. 43) as dual inhibitors of FGFR1 and HDAC.¹⁷⁴ Their studies suggested that the removal of a fluorine atom of **96a** ($IC_{50} = 58\ \text{nM}$) led to a decrease in HDAC6 inhibition with $IC_{50} = 132\ \text{nM}$ of the resulting compound **96b**. Conversely, the presence of a 3-ethoxy group (**96c**; $IC_{50} = 34\ \text{nM}$) showed better activity than the

compounds possessing methoxy (**96b**; $IC_{50} = 132\ \text{nM}$), isopropoxy (**96d**; $IC_{50} = 78\ \text{nM}$) and propoxy groups (**96e**; $IC_{50} = 132\ \text{nM}$). In addition, **96f** also showed better cellular inhibition against MCF-7 with $IC_{50} = 9\ \mu\text{M}$. The presence of an electron donor group at the *para*-position of the phenyl ring led to enhanced activity, as found in the case of **96f** ($IC_{50} = 41\ \text{nM}$) compared to **96g** ($IC_{50} = 103\ \text{nM}$) and **96h** ($IC_{50} = 281\ \text{nM}$). Moreover, the selectivity of these synthesized compounds was found to be significantly higher for HDAC6 compared to HDAC1 and HDAC8. Compound **96c** turned out to be the most effective with the highest HDAC6 activity but moderate FGFR1 activity.

Derivatives **96c** and **96e** were further studied for their docking with HDAC6 (Fig. 44). It was observed that the hydroxamic acid group of both derivatives chelated with zinc ions to enter the active site. Further, indazole group formed hydrophobic interactions with HDAC6, whereas the cap groups occupied the space outside the groove. The oxygen atom of the hydroxamic acid group formed a hydrogen bond with Tyr312 and the nitrogen atom formed a hydrogen bond with His143.

(ii) Epidermal growth factor/human epidermal growth factor receptor-2 (EGFR/HER-2) inhibitors

Zong *et al.* reported 3,3a,4,5-tetrahydro-2H-benzo[g] indazole derivatives (Fig. 45) of quinoxaline as EGFR/HER-2 dual inhibitors.¹⁷⁵ The structure–activity relationship (SAR) studies suggested that the presence of electron-donating groups on ring A led to higher enzymatic activity than the presence of electron-





Fig. 49 (a) Docking structure of **98e** with SGK1 structure PDB ID: 3HDM. (b) Docking structure of **98e** (grey) and **98d** (salmon) with SGK1 structure PDB ID: 3HDM.




**100a.** $R_1 = 2\text{-OCF}_3$, $R_2 = 5\text{-Br}$ **100b.** $R_1 = 2\text{-Br}$, $R_2 = 5\text{-OCF}_3$ **100c.** $R_1 = 2\text{-Cl}$, $R_2 = 4\text{-Cl}$ **100d.** $R_1 = 3\text{-F}$, $R_2 = 4\text{-F}$ **100e.** $R_1 = 3\text{-Cl}$, $R_2 = 4\text{-Cl}$ Fig. 50 Diaryl thiourea derivatives of 1*H*-indazole-3-amine as multiple kinase inhibitors.

withdrawing groups (**97b** > **97e** > **97a** > **97d** > **97c** with EGFR, $IC_{50} = 2.26, 8.26, 9.82, 15.67, 21.24 \mu\text{M}$ and HER-2, $IC_{50} = 3.68, 12.38, 11.43, 26.58$ and 18.43 , respectively). Also, the derivatives with a methoxy group at 4-position of ring B (**97f-j**) were more active than those with a methyl in the hydrogen substituents (**97k-t**). Interestingly, **97g** was found to be the most active among the series with $IC_{50} = 0.28$ and $1.26 \mu\text{M}$ for EGFR and HER-2, respectively.

Derivatives **97g** and **97r** were further studied for their docking with EGFR (Fig. 46 and 47), which suggested the hydrogen bonding of the methoxy oxygen of **97g** with Met769 and Gly697 with additional hydrogen bonding between the nitrogen of the quinoxaline group with Asp831. Further, the terminal phenyl moiety of **97g** participated in $\pi-\pi$ interaction with Phe699. This was also observed in the docking study of **97r**. Also, the oxygen of the tricyclic ring of **97r** was observed to form a hydrogen bond with Met769, whereas the nitrogen of the quinoxaline group participated in hydrogen bonding with Asp831 and Lys721.

(iii) Serine/threonine-protein kinase 1 (SGK1), tyrosine-protein kinase receptor (Tie2) and proto-oncogene tyrosine-protein kinase (SRC) inhibitors

Schoene *et al.* reported the synthesis of 2*H*-indazole derivatives (Fig. 48) as potential inhibitors of SGK1, Tie2 and SRC.¹⁷⁶ All the


Fig. 52 Docking structure of **100a** with Tie-2 (reproduced with permission; License Number: 5087591358694).

synthesized compounds showed at least 70% inhibition against at least one of the three kinases with almost equivalent activity against SGK1 and Tie2 (**98a-d**, **98f** and **99a** and **b**). 2-Fluoro-3-chloro-substitution and 2,3-dichloro derivatives were found to be superior to the unsubstituted phenyl derivatives. Interestingly, only the 5-hydroxy-6-aza-2*H*-indazole motif (**99**) showed significant SRC inhibition. Further, docking studies of **99e** with SGK1 (PDB ID 3HDM) showed high affinity ($2.13\text{--}221.15 \mu\text{M}$), which is in line with its IC_{50} value of 733 nM .

The docking studies of **98e** with SGK1 PDB ID 3HDM suggested that the azaindazole head forms hydrogen bonds with Ile179 and/or Asp177. In addition, sulfonamide formed a hydrogen bond with Asn277 or Ser108. Conversely, the methyl group of **98d** was exposed to the solvent front, which forced the orientation of **98d** into the front pocket than **98e**. In addition, the carboxylic group formed hydrogen bonding interactions with Ser108, and the nitrogen atom formed hydrogen bonding with Lys127 (Fig. 49).

(iv) Tie2, vascular endothelial growth factor-2 (VEGFR-2) and erythropoietin-producing human hepatocellular-B4 (EphB4) inhibitors

Sun *et al.* reported the design and synthesis of diaryl thiourea derivatives (Fig. 50) of 1*H*-indazole-3-amine as multiple kinase inhibitors.¹⁷⁷ Their studies suggested that these derivatives (**100a-e**) exhibit simultaneous activity against Tie2, VEGFR-2 and EphB4 with IC_{50} of less than 50 nM in all cases. Compound **100a** emerged as the most potent derivative with IC_{50} values of $3.45, 2.13$ and 4.71 nM against VEGFR-2, Tie2 and EphB4, respectively, supporting the importance of the 1*H*-indazole-3-amine moiety, which acts as a hinge binding group between the kinases under study, as confirmed by the docking studies. In accordance with its kinase inhibition, **100a** was found to inhibit the growth of 9 cancer cell lines (human liver cancer cell line; HepG2, SMMC-7721, human pancreatic cancer cell line; MIAPaCa-2, A431, human gastric cancer cell lines; MGC-803 and MKN28, human thyroid-carcinoma cancer cell-lines; 8505C, K1 and BCPAP) with IC_{50} values between $1.80\text{--}13.26 \mu\text{M}$.

Fig. 51 Docking structure of **100a** with VEGFR-2 (reproduced with permission; License Number: 5087591358694).




Fig. 53 Docking structure of **100a** with EphB4 (reproduced with permission; License Number: 5087591358694).

The most potent derivative **100a** was subjected to docking studies with the ATP pocket of VEGFR-2 (Fig. 51), Tie-2 (Fig. 52) and EphB4 (Fig. 53). Studies suggested that the amine group of the 1*H*-indazol-3-amine of **100a** participated in hydrogen bond formation with Asp1046 of VEGFR-2 and with Glu885 of Tie-2. In addition, the 1*H*-indazol-3-amine group formed two additional hydrogen bonds with Ala 905 of Tie-2. The 1*H*-indazol-3-amine group also formed hydrogen bonds with Met 696, Thr 693 and Glu 694 of EphB4 with additional hydrogen bond formation between the NH of urea and CO of Ile 621.

4. Multi target inhibitors

Wang *et al.* reported a series of 3-substituted indazole derivatives (Fig. 54) as potential multi-target kinase inhibitors.¹⁷⁸ Shifting of the *N*-(3-substituted)-3-(trifluoromethyl) benzamide moiety from the 6-position (**101**; 14% inhibitory rate) to the 5-position (**102**; 46.8% inhibitory rate) resulted in a significant decrease in activity in DDR2 according to the enzyme assay studies. Further optimization led to the formation of compound **104a** with $IC_{50} = 5.5$ nM. Reversing the amide substituent of **104a** and then with isopropyl group led to a further improvement of activity to $IC_{50} = 1.5$ nM and 1.2 nM for compounds **104b** and **104c**, respectively. Further optimization led to the formation of **104d**, **104e**, **104f** and **104g**, which possessed promising activity against FGFR1 and DDR2. Further, **104f** was also found to active against KG1, NCI-H716, SNU-16 and a human transitional cell carcinoma cancer cell line (UMUC14) with $IC_{50} = 108.4$, 31.8, 93.4 and 306.6 nM, respectively. Further drug-like studies supported that **104d** can be a potential drug for kinase inhibition.

Lu *et al.* discovered diarylurea derivatives (Fig. 55) as multi-kinase inhibitors.¹⁷⁹ The KINOMEscan™ system was used to study the binding assay of HL-40 against 450 human kinases at 10 μ M concentration, which suggested FLT3, CDK11, HIPK4, CDK8, DDR1, PDGFRb and KIT targeting compound **105**. Compound **105** was found to bind selectively to tyrosine-protein kinase (c-Kit), platelet-derived growth factor receptor beta (PDGFRb) and FLT3 with K_d values of 68.5, 140 and 375 nM,




Fig. 54 3-Substituted indazole derivatives as multi-target kinase inhibitors.






Fig. 55 Diarylurea derivatives as multi-kinases inhibitor.

respectively. The pharmacokinetic studies further suggested that compound **105** did not absorb rapidly in rat plasma given that the time to reach the maximum plasma concentration was 5.5 h. Further, compound **105** exhibited strong activity against an acute promyelocytic leukemia-derived cancer cell line (NB-4), human melanoma cancer cell line (SK-MEL-31 and SK-MEL-3) with IC_{50} values of 1.34, 1.77 and 1.12 μ M, respectively.

5. Conclusion and future perspectives

In this review, we discussed and highlighted the importance of indazole derivatives as kinase inhibitors. The easy synthesis of the derivatives of this core offers the scope of structure–activity studies with electron-donating and electron-withdrawing substituents around this versatile pharmacophore and their application in drug development and medicinal chemistry. The biological activities of indazole were demonstrated as kinase inhibitors including, tyrosine kinase, cyclin-dependent kinase, aurora kinase, EGFR, and VEGFR and their application against many cancer diseases such as breast cancer, non-small cell lung cancer, colon cancer, stomach cancer and liver cancers. Although multiple hypotheses have been proposed for the applications of indazole derivatives for kinase inhibitory activity, mono-kinase inhibition is the most widely accepted and considered to be a convincing target for the development of new indazole-based drug candidate. Some drugs with an indazole core are already in the market such as axitinib, linifanib, niraparib, and pazopanib, which show mono-kinase inhibitory activity. Thus, the exploration of the indazole scaffold will continue to identify many more biologically active kinase inhibitors in the future. The *in vitro* and *in vivo* activities of indazole derivatives are useful for future innovation. Progress in the development of indazole-based new targets for preventing the uncontrolled division of cells has been encouraging, but several drug candidates have unfortunately failed at various stages of clinical trials. These failures may be due to the interference by the drug candidates in many disease pathways, and thus the success rate to a particular target is very low. Current approaches to targeting kinase enzymes have shown adverse

side effects, which are attributed to their vital role in many other biological processes. In fact, the actual cause and realistic molecular targets need to be discovered and validated based on existing and new knowledge. To increase the efficiency, selective targeting should be actively pursued to reduce side effects, which is the main aim of cancer drugs. The indazole moiety has become a new drug candidate for anticancer activity, and the synthetic and clinical research communities need to collaborate to provide better and faster solutions in terms of dealing with new target for the effective control of cancer cells. Although active research groups are involved in developing indazole-based targets, there is no dedicated grand initiative in the area of clinical trials, which is responsible for the lag in activity based in this moiety. Further, we are hopeful that research groups will give their full efforts, and knowledge accumulated over the years will supplement the ongoing and forthcoming efforts in drug discovery to successfully develop new targets for the effective diagnosis of cancer in the near future. This article provides comprehensive and target-oriented information on the indazole core to synthetic and medicinal chemists for the development of potent and novel indazole derivatives as kinase inhibitors and new cancer therapy in the future.

Conflicts of interest

The author declares no conflict of interest.

Acknowledgements

We thank the DST-SERB, New Delhi (CRG/2018/002159) and CSIR, New Delhi [02(0310)/17/EMR-II] for the support of this research.

References

- 1 *Cancer*, <https://www.who.int/news-room/fact-sheets/detail/cancer>, accessed 1st March, 2020, 2020.
- 2 E. Eldon, *et al.*, *Concepts in Biology*, 2007, McGraw-Hill, p. 173.
- 3 S. Damodar, H. Terunuma, A. K. Sheriff, L. Farzana, S. Manjunath, R. Senthilkumar, G. Shatishkumar and S. Abraham, *J. Stem Cells Regen. Med.*, 2006, **1**, 40.
- 4 G. Sivaraman, A. Pandian, S. Bhaskar, K. Senthil, R. Senthilingarajan, V. Srinivasan, V. Deepapiya and S. Abraham, *J. Stem Cells Regen. Med.*, 2008, **4**, 13.
- 5 J. Abraham and J. Staffurth, *Medicine*, 2016, **44**, 30.
- 6 H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M. J. Garnett, W. Bottomley, N. Devis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmisou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B. A. Gusterson, C. Cooper, J. Shipley, D. H. Argrave, K. P. Jones, N. Maitland, G. C. Trench, G. J. Riggins, D. D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J. W. C. Ho, S. Y. Leung, S. T. Yuen, B. L. Weber, H. F. Seigler, T. L. Darrow, H. Paterson, R. Marais,



C. J. Marshall, R. Wooster, m. R. Stratton and P. A. Futreal, *Nature*, 2002, **417**, 949.

7 L. L. Ritterhouse and J. A. Barletta, *Semin. Diagn. Pathol.*, 2015, **32**, 400.

8 L. Yan, L. Zou, W. Zhao, Y. Wang, B. Liu, H. Yao and H. Yu, *Sci. Rep.*, 2015, **5**, 13718.

9 C. Inal, E. Yilmaz, B. Piperdi, R. Perez-Soler and H. Cheng, *Expert Opin. Emerging Drugs*, 2015, **20**, 597.

10 H. Kiyo and T. Naoe, *Int. J. Hematol.*, 2006, **83**, 301.

11 J. Gotlib and J. Cools, *Leukemia*, 2008, **22**, 1999.

12 P. Griseri, O. Garrone, A. L. Sardo, M. Monteverde, M. Rusmini, F. Tonissi, M. Merlano, P. Bruzzi, C. L. Nigro and I. Ceccherini, *Oncotarget*, 2016, **7**, 26465.

13 T. Haag, C. E. Herkt, S. K. Walesch, A. M. Richter and R. H. Dammann, *Genes Cancer*, 2014, **5**, 365.

14 D. Y. Fu, Z. M. Wang, B. L. Wang, L. Chen, W. T. Yang, Z. Z. Shen, W. Huang and Z. M. Shao, *Hum. Pathol.*, 2010, **41**, 48.

15 D. S. Kim, M. J. Kim, J. Y. Lee, S. M. Lee, J. E. Choi, S. Y. Lee and J. Y. Park, *Lung Cancer*, 2009, **65**, 247.

16 M. Kim, H. R. Jang, J. H. Kim, S. M. Noh, K. S. Song, J. S. Cho, H. Y. Jeong, J. C. Norman, P. T. Caswell, G. H. Kang, S.-Y. Kim, H.-S. Yu and Y. S. Kim, *Carcinogenesis*, 2008, **29**, 629.

17 T. Hunter and J. A. Cooper, *Annu. Rev. Biochem.*, 1985, **54**, 897.

18 H. Gharwan and H. Groninger, *Nat. Rev. Clin. Oncol.*, 2016, **13**, 209.

19 J. Cicenas and M. Valius M, *Nat. Rev. Clin. Oncol.*, 2011, **137**, 1409.

20 J. Cicenas, K. Kalyan, A. Sorokin, E. Stankunas, J. Levy, I. Meskinyte, V. Stankevicius, A. Kaupinis and M. Valius, *Ann. Transl. Med.*, 2015, **3**, 135.

21 J. Cicenas, K. Kalyan, A. Sorokin, A. Jatulyte, D. Valiunas, A. Kaupinis and M. Valius, *Cancers*, 2014, **6**, 2224.

22 J. Cicenas, *Nat. Rev. Clin. Oncol.*, 2016, **142**, 1995.

23 J. Cicenas and E. Cicenas, *Med. Oncol.*, 2016, **33**, 43.

24 B. B. Yang, P. Lum, A. Chen, R. Arends, L. Roskos, B. Smith and J. J. P. Ruix, *Clin. Pharmacokinet.*, 2010, **49**, 729.

25 Y. Krupitskaya and H. A. Wakelee, *Curr. Opin. Invest. Drugs*, 2009, **10**, 597.

26 K. R. A. Abdeltif and R. B. Bakr, *Med. Chem. Res.*, 2021, **30**, 31.

27 L. Garuti, M. Roberti and G. Bottegoni, *Curr. Med. Chem.*, 2014, **21**, 2284.

28 N. Pathak, E. Rathi, N. Kumar, S. G. Kini and C. M. Rao, *Mini-Rev. Med. Chem.*, 2020, **20**, 12.

29 Y. Wu, J. Xu, Y. Liu, Y. Zeng and G. Wu, *Front. Oncol.*, 2020, **10**, 592853.

30 R. Tandon, V. Luxami, H. Kaur, N. Tandon and K. Paul, *Chem. Rec.*, 2017, **17**, 956.

31 R. Tandon, I. Sing, V. Luxami, N. Tandon and K. Paul, *Chem. Rec.*, 2019, **19**, 362.

32 S. Vidyacharan, A. Murugan and D. S. Sharada, *J. Org. Chem.*, 2016, **81**, 2837.

33 A. H. Shinde, S. Vidyacharan and D. S. Sharada, *Org. Biomol. Chem.*, 2016, **14**, 3207.

34 S. Behrouz, *J. Heterocycl. Chem.*, 2017, **54**, 1863.

35 M. Jayanthi and P. Rajakumar, *J. Heterocycl. Chem.*, 2017, **54**, 3042.

36 H. Lavrard and F. Popowycz, *Synth.*, 2018, **50**, 998.

37 G. Bogonda, H. Y. Kim and K. Oh, *Org. Lett.*, 2018, **20**, 2711.

38 K. Holmes, O. L. Roberts, A. M. Thomas and M. J. Cross, *J. Heterocycl. Chem.*, 2007, **19**, 2003.

39 M. Francesca, R. Marco, B. Chiara and S. Silvia, *J. Med. Chem.*, 2012, **55**, 10797.

40 P. Fan-Wei, L. Da-Ke, Z. Qing-Wen, X. Yun-Gen and S. Lei, *Expert Opin. Ther. Pat.*, 2017, **27**, 987.

41 K. Czaja, J. Kujawski, P. Sliwa, R. Kurczab, R. Kujawski, A. Stodolna, A. Myslinska and M. K. Bernard, *Int. J. Mol. Sci.*, 2020, **21**, 4793.

42 O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455.

43 N. M. Y. Elsayed, R. A. T. Serya, M. F. Tolba, M. Ahmed, K. Barakat, D. A. A. E. Ella and K. A. M. Abouzid, *Bioorg. Chem.*, 2019, **82**, 340.

44 N. M. Y. Elsayed, D. A. A. E. Ella, R. A. T. Serya, M. F. Tolba, R. Shalabya and K. A. M. Abouzid, *MedChemComm*, 2016, **7**, 881.

45 J. Schlessinger, *Cell*, 2000, **103**, 211.

46 M. A. Lemmon and J. Schlessinger, *Cell*, 2010, **141**, 1117.

47 N. Itoh and D. M. Ornitz, *Trends Genet.*, 2004, **20**, 563.

48 D. M. Ornitz and N. Itoh, *Wiley Interdiscip. Rev.: Dev. Biol.*, 2015, **4**, 215.

49 B. Andrew and M. Moosa, *Nat. Rev. Drug Discovery*, 2009, **8**, 235.

50 D. Karel and A. Enrique, *Development*, 2010, **137**, 3731.

51 B. Gowardhan, D. A. Douglas, M. E. Mathers, A. B. McKie, S. R. C. McCracken, C. N. Robson and H. Y. Leung, *Br. J. Cancer*, 2005, **92**, 320.

52 A. N. Brooks, E. Kilgour and P. D. Smith, *Clin. Cancer Res.*, 2012, **18**, 1855.

53 J. Liu, Y. Wen, L. Gao, L. Gao, F. He, J. Zhou, J. Wang, R. Dai, X. Chen, D. Kang and L. Hu, *J. Enzyme Inhib. Med. Chem.*, 2020, **35**, 72.

54 L. D. Turner, A. J. Summers, L. O. Johnson, M. A. Knowles and C. W. G. Fishwick, *ACS Med. Chem. Lett.*, 2017, **8**, 1264.

55 J. Cui, X. Peng, D. Gao, Y. Dai, J. Ai and Y. Li, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 3782.

56 J. Liu, X. Peng, Y. Dai, W. Zhang, S. Ren, J. Ai, M. Geng and Y. Li, *Org. Biomol. Chem.*, 2015, **13**, 7643.

57 Z. Zhang, D. Zhao, Y. Dai, M. Cheng, M. Geng, J. Shen, Y. Ma, J. Ai and B. Xiong, *Molecules*, 2016, **21**, 1407.

58 J. Liu, X. Peng, Y. Dai, W. Zhang, S. Ren, J. Ai, M. Geng and Y. Li, *Org. Biomol. Chem.*, 2015, **13**, 7643.

59 F. Ciardiello and G. Tortora, *N. Engl. J. Med.*, 2008, **359**, 1160.

60 S. Tomassi, J. Lategahn, J. Engel, M. Keul, H. L. Tumbrink, J. Ketzer, T. M. Hlenberg, M. Baumann, C. Schultz-Fademrecht, S. Bauer and D. Rauh, *J. Med. Chem.*, 2017, **60**, 2361.

61 L. J. Berg, L. D. Finkelstein, J. A. Lucas and P. L. Schwartzberg, *Annu. Rev. Immunol.*, 2005, **23**, 549.

62 X. C. Liao and D. R. Littman, *Immunity*, 1995, **3**, 757.



63 E. M. Schaeffer, J. Debnath, G. Yap, D. McVicar, X. C. Liao, D. R. Littman, A. Sher, H. E. Varmus, M. J. Lenardo and P. L. Schwartzberg, *Science*, 1999, **284**, 638.

64 D. J. Fowell, K. Shinkai, X. C. Liao, R. L. Coffman, D. R. Littman and R. M. Locksley, *Immunity*, 1999, **11**, 399.

65 J. Kaukonen, E. R. Savolainen and A. Palotie, *Leuk Lymphoma*, 1999, **32**, 513.

66 J. Shin, S. Monti, D. J. Aires, M. Duvic and T. S. Kupper, *Blood*, 2007, **110**, 3015.

67 A. Heifetz, G. Trani, M. Aldeghi, C. H. MacKinnon, P. A. McEwan, F. A. Brookfield, E. I. Chudyk, M. Bodkin, Z. Pei, J. D. Burch and D. F. Ortwine, *J. Med. Chem.*, 2016, **59**, 4352.

68 E. J. Huang and L. F. Reichardt, *Annu. Rev. Neurosci.*, 2001, **24**, 677.

69 J. M. Frade and Y. A. Barde, *Bioessays*, 1998, **20**, 137.

70 T. D. Patel, A. Jackman, F. L. Rice, J. Kucera and W. D. Snider, *Neuron*, 2000, **25**, 345.

71 H. K. Teng, K. K. Teng, R. Lee, S. Wright, S. Tevar, R. D. Almeida, P. Kermani, R. Torkin, Z.-Y. Chen, F. S. Lee, R. T. Kraemer, A. Nyljaer and B. L. Hampstead, *J. Neurosci.*, 2005, **25**, 5455.

72 E. Cocco, M. Scaltriti and A. Drilon, *Nat. Rev. Clin. Oncol.*, 2018, **15**, 731.

73 S. N. Chen, B. Schneider, S. Nagel, R. Geffers, M. Kaufmann, H. Quentmeier, H. G. Drexler and R. A. F. MacLeod, *Blood*, 2009, **22**, 5042.

74 C. Lagadec, S. Meignan, E. Adriaenssens, B. Foveau, E. Vanhecke, R. Romon, R. A. Toillon, B. Oxombré, H. Hondermarck and X. L. Bourhis, *Oncogene*, 2009, **28**, 1960.

75 A. M. Lange and H. W. Lo, *Cancers*, 2018, **10**, 105.

76 H. Shirahashi, E. Toriihara, Y. Suenaga, H. Yoshida, K. Akaogi, Y. Endou, M. Wakabayashi and M. T. Bioorg, *ACS Med. Chem. Lett.*, 2019, **29**, 2320.

77 J. R. Woodgett, *EMBO J.*, 1990, **9**, 2431–2438.

78 H. Zheng, H. Saito, S. Masuda, X. Yang and Y. Takano, *Anticancer Res.*, 2007, **27**, 3561.

79 G. Lin, B. Liu, Z. Meng, Y. Liu, X. Li, X. Wu, Q. Zhou and K. Xu, *Exp. Cell Res.*, 2017, **352**, 364.

80 M. Farago, I. Dominguez, E. Landesman-Bollag, X. Xu, A. Rosner, R. D. Cardiff and D. C. Seldin, *Cancer Res.*, 2005, **65**, 5792.

81 Z. Tan, H. Zheng, X. Liu, W. Zhang, J. Zhu, G. Wu, L. Cao, J. Song, S. Wu, L. Song and J. Li, *Oncotarget*, 2016, **7**, 24076.

82 H. Shen, L. Li, S. Yang, D. Wang, S. Zhong, J. Zhao and J. Tang, *Gene*, 2016, **593**, 84.

83 C. Ma, J. Wang, Y. Gao, T.-W. Gao, G. Chen, K. A. Bower, M. Odetallah, M. Ding, Z. Ke and J. Luo, *Cancer Res.*, 2007, **67**, 7756.

84 H.-J. Qiu, X.-H. Lu, S.-S. Yang, C.-Y. Weng, E.-K. Zhang and F.-C. Chen, *Biomed. Pharmacother.*, 2016, **82**, 117.

85 G. Garcea, M. M. Manson, C. P. Neal, C. J. Pattenden, C. D. Sutton, A. R. Dennison and D. P. Berry, *Curr. Cancer Drug Targets*, 2007, **7**, 209.

86 B. Marchand, D. Arsenault, A. Raymond-Fleury, F.-M. Boisvert and M.-J. Boucher, *J. Biol. Chem.*, 2015, **290**, 5592.

87 H.-W. Yang, G.-H. Liu, Y.-Q. Liu, H.-C. Zhao, Z. Yang, C.-L. Zhao, X.-F. Zhang and H. Ye, *Biomed. Pharmacother.*, 2016, **83**, 593.

88 W. Zhou, Y. Li, S. Gou, J. Xiong, H. Wu, C. Wang, H. Yan and T. Liu, *Oncotarget*, 2015, **6**, 37557.

89 N. R. Park, J. H. Cha, J. W. Jang, S. H. Bae, B. Jang, J.-H. Kim, W. Hur, J. Y. Choi and S. K. Yoon, *Biochem. Biophys. Res. Commun.*, 2016, **477**, 568.

90 L. Zhuang, X. Wang, Z. Wang, X. Ma, B. Han, H. Zou, Z. Wu, S. Dong, Z. Qu, Y. Zang and L. Wu, *Cell Death Dis.*, 2017, **8**, 2804.

91 A. E. Abrahamsson, I. Geron, J. Gotlib, K.-H. T. Da, C. F. Barroga, I. G. Newton, F. J. Giles, J. Durocher, R. S. Creusot, M. Karimi, C. Jones, J. L. Zehnder, A. Keating, R. S. Negrin, I. L. Weissman and C. H. M. Jamieson, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 3925.

92 F. Zhou, L. Zhang, T. V. Laar, H. V. Dam and P. T. Dijke, *Mol. Biol. Cell*, 2011, **22**, 3533.

93 F. Prati, R. Buonfiglio, G. Furlotti, C. Cavarischia, G. Mangano, R. Picollo, L. Oggianu, A. D. Matteo, S. Olivieri, G. Bovi, P. F. Porceddu, A. Reggiani, B. Garrone, F. P. D. Giorgio and R. Ombrato, *ACS Med. Chem. Lett.*, 2020, **11**, 825.

94 R. Ombrato, N. Cazzolla, F. Mancini and G. Mangano, *J. Chem. Inf. Model.*, 2015, **55**, 2540.

95 G. Furlotti, M. A. Alisi, N. Cazzolla, P. Dragone, L. Durando, G. Magaro, F. Mancini, G. Mangano, R. Ombrato, M. Vitiello, A. Armiratti, V. Capurro, M. Lanfranco, G. Ottonello, M. Summa and A. Reggiani, *J. Med. Chem.*, 2015, **58**, 8920.

96 E. A. Nigg, *Nat. Rev. Mol. Cell Biol.*, 2001, **2**, 21.

97 Y. Cirak, Y. Furuncuoglu, O. Yapicier, A. Aksu and E. Cubukcu, *J. Buon.*, 2015, **20**, 1414.

98 I. Ferchichi, S. S. Hannachi, A. Baccar, R. M. Triki, J. Y. Cremet, K. B. Romdhane, C. Prigent and A. B. A. E. Gaaied, *Dis. Markers*, 2013, **34**, 63.

99 Y. Zhang, C. Jiang, H. Li, F. Lv, X. Li, X. Qian, L. Fu, B. Xu and X. Guo, *Int. J. Clin. Exp. Pathol.*, 2015, **8**, 751.

100 A. Zekri, V. Lesan, S. H. Ghaffari, M. H. Tabrizi and M. H. Oncol. Res., 2012, **20**, 241.

101 K. Honma, R. Nakanishi, T. Nakanoko, K. Ando, H. Saeki, E. Oki, M. Iimori, H. Kitao, Y. Kakeji and Y. Maehara, *Surg. Today*, 2014, **44**, 454.

102 A. Katsha, A. Belkhiri, L. Goff and W. El-Rifai, *Mol. Cancer*, 2015, **14**, 106.

103 T. V. Do, F. Xiao, L. E. Bickel, A. J. Klein-Szanto, H. B. Pathak, X. Hua, C. Howe, S. W. O'Brien, M. Maglaty, J. A. Ecsedy, S. Litwin, E. A. Golemis, R. J. Schilder, A. K. Godwin and D. C. Connolly, *Oncogene*, 2014, **33**, 539.

104 G. Yang, B. Chang, F. Yang, X. Guo, K. Q. Cai, X. S. Xiao, H. Wang, S. Sen, M. C. Hung, G. B. Mills, S. Chang, A. S. Multani, I. Mercado-Uribe and J. Liu, *Clin. Cancer Res.*, 2010, **16**, 3171.



105 B. Davidson, D. A. Nymoen, B. V. Elgaaen, A. C. Staff, C. G. Tropé, J. Kærn, R. Reich and T. E. Falkenthal, *Virchows Arch.*, 2014, **464**, 701.

106 L. Casorzo, C. Dell'Aglio, I. Sarotto and M. Risio, *Hum. Pathol.*, 2015, **46**, 411.

107 S. Hosseini, S. Hashemzadeh, M. A. Estiar, R. Ebrahizadeh, M. B. Fakhree, B. Yousefi, S. Sheikholeslami, M. H. Modarresi and E. Sakhinia, *Clin. Lab.*, 2015, **61**, 475.

108 S. Fujii, V. Srivastava, A. Hegde, Y. Kondo, L. Shen, K. Hoshino, Y. Gonzalez, J. Wang, K. Sasai, X. Ma, H. Katayama, M. R. Estecio, S. R. Hamilton, I. Wistuba, J.-P. J. Issa and S. Sen, *Tumor Biol.*, 2015, **36**, 8147.

109 C.-F. Chang, W.-H. Lin, Y.-Y. Ke, Y.-S. Lin, W.-C. Wang, C.-H. Chen, P.-C. Kuo, J. T. A. Hsu, B.-J. Uang and H.-P. Hsieh, *Eur. J. Med. Chem.*, 2016, **124**, 186.

110 P. Song, M. Chen, X. Ma, L. Xu, T. Liu, Y. Zhou and Y. Hu, *Bioorg. Med. Chem.*, 2015, **8**, 1858.

111 M. Narlik-Grassow, C. Blanco-Aparicio and A. Carnero, *Med. Res. Rev.*, 2014, **34**, 136.

112 M. C. Nawijn, A. Alendar and A. Berns, *Nat. Rev. Cancer*, 2011, **11**, 23.

113 U. Warnecke-Eberz, E. Bollschweiler, U. Drebber, R. Metzger, S. E. Baldus, A. H. Holscher and S. Monig, *Anticancer Res.*, 2009, **29**, 4451.

114 H. C. Zheng, K. Tsuneyama, H. Takahashi, S. Miwa, T. Sugiyama, B. K. Popivanova, C. Fujii, K. Nomoto, N. Mukaida and Y. Takano, *Nat. Rev. Clin. Oncol.*, 2008, **134**, 481.

115 H. Hu, X. Wang, G. Ka, Y. Chan, J. H. Chang, S. Do, J. Drummond, E. Allen, W. Lee, L. Justin, J. P. Lyssikatos, J. Murray, J. G. Moffat, Q. Chao, V. Tsui, H. Wallweber and A. Kolesnikov, *Bioorg. Med. Chem. Lett.*, 2015, **25**, 5258.

116 H.-L. Wang, V. J. Cee, F. Chavej Jr, B. A. Lanman, A. B. Reed, B. Wu, N. Guerrero, J. R. Lipford, C. Sastri, J. Winston, K. L. Andrews, X. Huang, M. R. Lee, C. Mohr, Y. Xu, Y. Zhou and A. S. Taske, *Bioorg. Med. Chem. Lett.*, 2015, **4**, 834.

117 C. Helmke, S. Becker and K. Strehardt, *Oncogene*, 2016, **35**, 135.

118 S. Zitouni, C. Nabais, S. C. Jana, A. Guerrero and M. Bettencourt-Dias, *Nat. Rev. Mol. Cell Biol.*, 2014, **15**, 433.

119 A. J. Holland, W. Lan, S. Niessen, H. Hoover and D. W. Cleveland, *J. Cell Biol.*, 2010, **188**, 191.

120 K. Shinmura, N. Kurabe, M. Goto, H. Yamada, H. Natsume, H. Konno and H. Sugimura, *Mol. Biol. Rep.*, 2014, **41**, 6635.

121 M. Marina and H. I. Saavedra, *Front. Biosci.*, 2014, **19**, 352.

122 S.-W. Li, Y. Liu, P. B. Sampson, N. K. Patel, B. T. Forrest, L. Edwards, R. Laufer, M. Feher, F. Ban, D. E. Awrey, R. Hodgson, I. Beletskaya, G. Mao, J. M. Mason, X. Wei, X. Luo, R. Kiarash, E. Green, T. W. Mak, G. Pan and H. W. Pauls, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 4625.

123 L. Julian and M. F. Olson, *Small GTPases*, 2014, **5**, 29846.

124 M. Amano, M. Nakayama and K. Kaibuchi, *Cytoskeleton*, 2010, **67**, 545.

125 C. A. Street, A. A. Routhier, C. Spencer, A. L. Perkins, K. Masterjohn, A. Heckathron, J. Montalvo, E. A. Dennstedt and B. A. Bryan, *Internet J. Oncol.*, 2010, **37**, 1297.

126 M. Morgan-Fisher, U. M. Wewer and A. Yoneda, *J. Histochem. Cytochem.*, 2013, **61**, 185.

127 Y. Yao, R. Li, X. Liu, F. Yang, Y. Yang, X. Li, X. Shi, T. Yuan, L. Fang, G. Du, X. Jiao and P. Xie, *Molecules*, 2017, **22**, 1766.

128 S. M. Storm and U. R. Rapp, *Toxicol. Lett.*, 1993, **67**, 201.

129 A. Zebisch, P. B. Staber, A. Delavar, C. Bodner, K. Hiden, K. Fischereder, M. Janakiraman, W. Linkesch, H. W. Auner, W. Emberger, C. Windpassinger, M. G. Schimek, G. Hoefer, J. Troppmair and H. Sill, *Cancer Res.*, 2006, **66**, 3401.

130 W. Aman, J. Lee, M. Kim, S. Yang, H. Jung and J.-M. Hah, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 1188.

131 W. Zhang and H. T. Liu, *Cell Res.*, 2002, **12**, 9.

132 M. Cargnello and P. P. Roux, *Microbiol. Mol. Biol. Rev.*, 2011, **75**, 50.

133 V. Leo, A. Stefanachi, C. Nacci, F. Leonetti, M. D. Candia, A. Carotti, C. D. Altomare, M. Montagnani and S. Cellamare, *J. Pharm. Pharmacol.*, 2015, **67**, 1380.

134 M. Kawamura, D. W. McVicar, J. A. Johnston, T. B. Blake, Y.-Q. Chen, B. K. Lal and J. R. Ortaldo, *Proc. Natl. Acad. Sci. U. S. A.*, 1994, **91**, 6374.

135 C. Schindle, *Exp. Cell Res.*, 1999, **253**, 7.

136 J. L. Spivak, *Ann. Intern. Med.*, 2010, **152**, 300.

137 D. Ungureanu, J. Wu, T. Pekkala, Y. Nirajan, C. Young, O. N. Jensen, C.-F. Xu, T. A. Neubert, R. C. Skoda, S. R. Hubbard and O. Silvennoinen, *Nat. Struct. Mol. Biol.*, 2011, **18**, 971.

138 H. Sakaguchi, Y. Okuno, H. Muramatsu, K. Yoshida, Y. Shiraishi, M. Takahashi, A. Kon, M. Sanada, K. Chiba, H. Tanaka, H. Makishima, X. Wang, Y. Xu, S. Doisaki, A. Hama, K. Nakanishi, N. Yoshida, J. P. Maciejewski, S. Miyano, S. Ogawa and S. Kojima, *Nat. Genet.*, 2013, **45**, 937.

139 A. Ritzen, M. D. Sorensen, K. N. Dack, D. R. Greve, A. Jerre, M. A. Carnerup, K. A. Rytved and J. Bagger-Bahnsen, *ACS Med. Chem. Lett.*, 2016, **7**, 641.

140 D. Bajusz, G. G. Ferenczy and G. M. Keseru, *J. Chem. Inf. Model.*, 2016, **56**, 234.

141 P. Pissios, D. J. Trombly, I. Tzameli and E. Maratos-Flier, *Endocrinology*, 2003, **8**, 3514.

142 H. Igawa, M. Takahashi, M. Ikoma, H. Kaku, K. Kakegawa, A. Kina, J. Aida, S. Okuda, Y. Kawata, T. Noguchi, N. Hotta, S. Yamamoto, M. Nakayama, Y. Nagisa, S. Kasai and T. Maekawa, *Bioorg. Med. Chem.*, 2016, **11**, 2504.

143 Y. Ma, C. C. Han, Q. Huang, W. Y. Sun and W. Wei, *Oncol. Rep.*, 2016, **35**, 3068–3074.

144 M. J. Billard, D. J. Fitzhugh, J. S. Parker, J. M. Brozowski, M. W. McGinnis, R. G. Timoshchenko and D. S. Serafin, *PLoS One*, 2016, **11**, e0152856.

145 E. V. Gurevich, J. J. Tesmer, A. Mushegian and V. V. Gurevich, *Pharmacol. Ther.*, 2012, **133**, 40–69.

146 R. Bouley, H. V. Waldschmidt, M. C. Cato, A. Cannavo, J. Song, J. Y. Cheung, X.-Q. Yao, W. J. Koch, S. D. Larsen and J. J. G. Tesmer, *Mol. Pharmacol.*, 2017, **92**, 707.



147 H. Oka, Y. Chatani, R. Hoshino, O. Ogawa, Y. Kakehi, T. Terachi, Y. Okada, M. Kawaichi, M. Kohno and O. Yoshida, *Cancer Res.*, 1995, **55**, 4182.

148 R. Hoshino, Y. Chatani, T. Yamori, T. Tsuruo, H. Oka, O. Yoshida, Y. Shimada, S. Ari-i, H. Wada, J. Fujimoto and M. Kohno, *Oncogene*, 1999, **18**, 813.

149 L. Li, F. Liu, N. Jin, S. Tang, Z. Chen, X. Yang, J. Ding, M. Geng, L. Jiang, M. Huang and J. Cao, *Bioorg. Med. Chem. Lett.*, 2016, **26**, 2600.

150 C. Lechauve, J. Keith, E. Khandros, S. Fowler, K. Mayberry, A. Freiwan, C. S. Thom, P. Delbini, E. B. Romero, J. Zhang, I. Motta, H. Tilman, M. D. Cappellini, M. Kundu and M. J. Weiss, *Sci. Transl. Med.*, 2019, **11**, 4881.

151 Y. Quan, H. Lei, W. Wahafu, Y. Liu, H. Ping and X. Zhang, *Biomed. Pharmacother.*, 2019, **120**, 109490.

152 S. D. Wood, W. Grant, I. Adrados, J. Y. Choi, J. M. Alburger, D. R. Duckett and W. R. Roush, *ACS Med. Chem. Lett.*, 2017, **8**, 1258.

153 S. L. Carroll and N. Ratner, *Glia*, 2008, **56**, 1590.

154 B. C. Widemann, *Curr. Oncol. Rep.*, 2009, **11**, 322.

155 H. Tabusa, T. Brooks and A. J. Massey, *Mol. Cancer Res.*, 2013, **11**, 109.

156 H. Y. Chow, A. M. Jubb, J. N. Koch, Z. M. Jaffer, D. Stepanova, D. A. Campbell, S. G. Duran, M. O'Farrell, K. Q. Cai, A. J. P. Klein-Szanto, J. S. Gutkind, K. P. Hoeflich and J. Chernoff, *Cancer Res.*, 2012, **72**, 5966.

157 N. M. Baker, H. Y. Chow, J. Chernoff and C. J. Der, *Clin. Cancer Res.*, 2014, **20**, 4740–4746.

158 C. C. Ong, A. M. Jubb, P. M. Haverty, W. Zhou, V. Tran, T. Truong, H. Turley, T. O'Brien, D. Vucic, A. L. Harris, M. Belvin, L. S. Friedman, E. M. Blackwood, H. Koeppen and K. P. Hoeflich, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 7177.

159 S. Jagadeeshan, Y. R. Krishnamoorthy, M. Singhal, A. Subramanian, J. Mavuluri, A. Lakshmi, A. Roshini, G. Baskar, M. Ravi, L. D. Joseph, K. Sadasivan, A. Krishnan, A. S. Nair and G. Venkatraman, *Oncogene*, 2015, **34**, 455–464.

160 M. Zhang, X. Fang, C. Wang, C. Huang, M. Wang, L. Zhu, Z. Wang, Y. Gao, T. Zhang, H. Liu, Y. Zhang, S. Lu, T. Lu, Y. Chen and H. Li, *Eur. J. Med. Chem.*, 2020, **203**, 112517.

161 B. D. Looyenga, K. A. Furge, K. J. Dykema, J. Koeman, P. J. Swiatek, T. J. Giordano, A. B. West, J. H. Resau, B. T. The and J. P. MacKeigan, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 1439.

162 Z.-C. Jiang, X.-J. Chen, Q. Zhou, X.-H. Gong, X. Chen and W.-J. Wu, *Internet J. Oncol.*, 2019, **55**, 21.

163 J. D. Scott, D. E. DeMong, T. J. Greshock, K. Basu, X. Dai, J. Harris, A. Hruza, S. W. Li, S.-I. Lin, H. Liu, M. K. Macala, Z. Hu, H. Mei, H. Zhang, P. Walsh, M. Poirier, Z.-C. Shi, L. Xiao, G. Agnihotri, M. A. S. Baptista, J. Columbus, M. J. Fell, L. A. Hyde, R. Kuvelker, Y. Lin, C. Mirescu, J. A. Morrow, Z. Yin, X. Zhang, X. Zhou, R. K. Chang, M. W. Embrey, J. m. Sanders, H. E. Tiscia, R. E. Drolet, J. T. Kern, S. M. Sur, J. J. Renger, M. T. Bilodeau, M. E. Kennedy, E. M. Parker, A. W. Stamford, R. Nargund, J. A. McCauley and M. W. Miller, *J. Med. Chem.*, 2017, **60**, 2983.

164 R. Katso, K. Okkenhaug, K. Ahmadi, S. White, J. Timms and M. D. Waterfield, *Annu. Rev. Cell Dev. Biol.*, 2001, **17**, 615.

165 J. A. Engelman, J. Luo and L. C. Cantley, *Nat. Rev. Genet.*, 2006, **7**, 606.

166 V. Asati, D. K. Mahapatra and S. K. Bharti, *Eur. J. Med. Chem.*, 2016, **109**, 314.

167 B. T. Hennessy, D. L. Smith, P. T. Ram, Y. Lu and G. B. Mills, *Nat. Rev. Drug Discovery*, 2005, **4**, 988.

168 S. Dugar, F. P. Hollinger, D. Mahajan, S. Sen, B. Kuila, R. Arora, Y. Pawar, V. Shinde, M. Rahinj, K. K. Kapoor, R. Bhumkar, S. Rai and R. Kulkarni, *ACS Med. Chem. Lett.*, 2015, **6**, 1190.

169 G. Salvatore, T. C. Nappi, P. Salerno, Y. Jiang, C. Garbi, C. Ugolini, P. Miccoli, F. Basolo, M. D. Castellone, A. M. Cirafici, R. M. Mallilo, A. Fusco, M. L. Bittner and M. Santoro, *Cancer Res.*, 2007, **67**, 10148–10157.

170 B. P. Kaistha, T. Honstein, V. Muller, S. Bielak, M. Sauer, R. Kreider, M. Fassan, A. Scarpa, C. Schmees, H. Volkmer, T. M. Gress and M. Buchholz, *Br. J. Cancer*, 2014, **111**, 1780.

171 J. Daniel, J. Coulter, J.-H. Woo, K. Wilsbach and E. Gabrielson, *Proc. Natl. Acad. Sci. U. S. A.*, 2011, **108**, 5384.

172 X. Liu, W. Liao, Q. Yuan, Y. Ou and J. Huang, *Oncotarget*, 2015, **6**, 34309.

173 Y. Liu, Y. Lang, N. K. Patel, G. Ng, R. Laufer, S. W. Li, L. Edwards, B. Forrest, P. B. Sampson, M. Feher, F. Ban, D. E. Awrey, I. Beletskaya, G. Mao, R. Hodgson, O. Plotnikova, W. Qiu, N. Y. Chirgadze, J. M. Mason, X. Wei, D. C.-C. Lin, Y. Che, R. Kiarash, B. Madeira, G. C. Fletcher, T. W. Mak, M. R. Bray and H. W. Pauls, *J. Med. Chem.*, 2015, **58**, 3366.

174 J. Liu, C. Qian, Y. Zhu, J. Cai, Y. He, J. Li, T. Wang, H. Zhu, Z. Li, W. Li and L. Hu, *Bioorg. Med. Chem.*, 2018, **26**, 747.

175 X. Zong, J. Cai, J. Chen, C. Sun, L. Lib and M. Ji, *RSC Adv.*, 2015, **5**, 24814–24823.

176 J. Schoene, T. Gazz, P. Lindemann, M. Christmann, A. Volkamer and M. Nazar, *ChemMedChem*, 2019, **14**, 1514.

177 Y. Sun, Y. Shan, C. Li, R. Si, X. Pan, B. Wang and J. Zhang, *Eur. J. Med. Chem.*, 2017, **141**, 373.

178 Q. Wang, Y. Dai, Y. Ji, H. Shi, Z. Guo, D. Chen, Y. Chen, X. Peng, Y. Gao, X. Wang, L. Chen, Y. Jiang, M. Geng, J. Shen, J. Ai and B. Xiong, *Eur. J. Med. Chem.*, 2019, **163**, 671.

179 Y.-Y. Lu, C.-R. Zhao, R.-Q. Wang, W.-B. Li and X.-J. Qu, *Biomed. Pharmacother.*, 2015, **69**, 255.

